

**MONASH
ADDICTION
RESEARCH
CENTRE**

2020 – 2021
ANNUAL REPORT

2020 – 2021 SNAPSHOT

 **120**
MEMBERS

MARC'S MEMBERSHIP HAS GROWN TO 120 ACADEMICS FROM ACROSS MONASH MAKING IT ONE OF THE LARGEST ADDICTION RESEARCH CENTRES IN THE WORLD.

198 
PUBLICATIONS

OUR MEMBERS PUBLISHED 198 PEER-REVIEWED JOURNAL ARTICLES IN THE FIELD OF ADDICTION, WITH 69% PUBLISHED IN Q1 JOURNALS.

 **\$9.1M**

OUR MEMBERS RECEIVED OVER \$9.1M IN FUNDING TO COMPLETE ADDICTION BASED RESEARCH.

124 
MEDIA MENTIONS

MARC RESEARCHERS APPEARED IN THE MEDIA MORE THAN 120 TIMES, INCLUDING ACROSS RADIO, TV, ONLINE & PRINT MEDIA.

2 
SCHOLARSHIPS

WE AWARDED TWO MARC-CENTRE FOR MEDICINE USE AND SAFETY (CMUS) COLLABORATIVE PHD SCHOLARSHIPS

CONTENTS

| | |
|----------------------------|----|
| ABOUT US | 3 |
| MESSAGE FROM THE DIRECTORS | 5 |
| GOVERNANCE | 6 |
| FUNDING SUCCESS | 12 |
| CURRENT RESEARCH | 16 |
| THOUGHT LEADERSHIP | 22 |
| KEY ACTIVITIES | 24 |
| POLICY | 25 |
| MARC PhD STUDENTS | 27 |
| MEDIA | 28 |
| OUR COLLABORATORS | 30 |
| PUBLICATIONS | 32 |

ABOUT US

The Monash Addiction Research Centre (MARC) brings together world-leading expertise from across Monash University and the sector to provide solutions to the challenges of addiction.

We have 120 academic members across 30 departments in six faculties and two institutes, making us one of the largest addiction centres in the world.

Our mission is to provide national thought leadership, education, and research excellence to develop, deliver and evaluate effective policy and practice approaches for addiction.

USING DATA FOR IMPACT

We generate and leverage multiple unique datasets, and provide timely and accessible insights to drive policy and practice change.

TRANSFORMING PRACTICE

We work to transform practice through co-designing, trialling and implementing novel evidence-based approaches. We work with community partners in the Frankston-Mornington Peninsula, those with lived experience of addiction, and other key stakeholders to develop local solutions that can be scaled nationally.

CHANGING THE CONVERSATION

We directly address stigma and community perceptions of addiction by bringing together multiple perspectives, including lived experience, through thought leadership, expert commentary and evidence dissemination.

ENABLING THE WORKFORCE

We build the expertise of individuals working in addiction and other frontline workforces, and the capacity of the treatment sector more broadly. We achieve this through development and delivery of short courses, embedded addiction curricula and work-integrated learning opportunities. We work with government partners to deliver effective reforms in addiction and mental health care.

OUR AIM

MARC is dedicated to finding solutions that transform the way we think about and respond to addiction.



visit us at: monash.edu/medicine/ehcs/marc



A MESSAGE FROM THE DIRECTORS

We are pleased to present the Monash Addiction Research Centre's Annual Report for 2020-2021.

Despite another challenging year due to the impacts of COVID-19 and ongoing lockdowns, MARC has continued to forge ahead with its activities and initiatives aimed at strengthening the reputation of the Centre, and building opportunities for Phd students and early to mid-career researchers within MARC.

Our members have had another successful year, securing more than \$9M in research funding and publishing over 198 peer-reviewed articles. This success continues to demonstrate the enormous impact our members are making in the field of addiction, and the importance of interdisciplinary collaboration in finding solutions to the challenges of addiction.

Since August last year, we have delivered ten webinars as part of our interdisciplinary webinar series, attracting over 2000 registrations in total. The series brings together addiction researchers, clinicians and other experts to discuss emerging research and challenges in the addiction field, with 25 of our members participating in the webinars and presenting their research.

We have also continued to offer professional development opportunities for our EMCRs, delivering online workshops covering social media, data linkage, productive writing techniques and science communication. In July this year, we established the MARC PhD network, which brings together Monash PhD students from various disciplines, departments and faculties interested in or currently undertaking addiction-related research. The network connects students researching similar areas, encourages collaboration, promotes students' work, and provides opportunities to participate in addiction-related research

events and networking opportunities.

Over the past 12 months, the Centre has been actively involved in several submissions and inquiries, including the Royal Commission into Victoria's Mental Health System, the Inquiry into the Use of Cannabis in Victoria, the Australian Commission on Safety and Quality in Health Care - National Opioid Analgesic Stewardship Program, and the Public Consultation for the Post-market Review of Opiate Dependence Treatment Program Medicines. The recommendations made to these inquiries and programs are informed by the collaborative work of the Centre and are part of our ongoing policy and advocacy work.

On behalf of MARC, we would like to thank our advisory board, our members, research partners and the community for their ongoing support and contribution to the Centre and we look forward to seeing everyone in 2022.

PROFESSOR DAN LUBMAN
Director

ASSOCIATE PROFESSOR SUZANNE NIELSEN
Deputy Director

Centre Director, Professor Dan Lubman AM, oversees the Centre's research and operations while playing a key role in the development of industry engagement activities.

Deputy Director, Associate Professor Suzanne Nielsen, is instrumental in the development of research collaborations and plays a critical role in the strategic development of key initiatives in the Frankston Mornington Peninsula region. Other core staff include members of the MARC research team and strategy and business operations team.

GOVERNANCE

Executive Management / Senior Leadership



PROFESSOR DAN LUBMAN
Director



ASSOCIATE PROFESSOR SUZANNE NIELSEN
Deputy Director

Strategy and Business Operations



KRISTA CRAWFORD
Executive Assistant



KELLIE RUDLIN
Senior Communications Adviser

Research Staff



DR TINA LAM
Research Fellow



DR TING XIA
Research Fellow



DR LEANNE FRANCIA
Research Officer



DR ALI CHEETHAM
Research Officer



LOUISA PICCO
Research Assistant



Professor Dan Lubman AM and the Honourable Linda Dessau AC

Professor Dan Lubman appointed Member of the Order of Australia

In January this year, MARC Director, Professor Dan Lubman, was appointed a Member of the Order of Australia (AM) in the Australia Day Honours List for his significant service to medical education, research, treatment and policy in the field of addiction. Dan received his official AM at an Investiture Ceremony held at Government House in April 2021.

Reflecting on his appointment Dan said he was thrilled and humbled to be recognised in this way, and the acknowledgement was a reflection of how perceptions of addiction are changing.

“Addiction remains the most stigmatised health condition, but to be honoured in this way recognises the importance of addressing a public health issue that costs Australia and Australian families so much. I'm just delighted that our continued efforts to improve health outcomes for Australians affected by addiction have been recognised in this way.”

MARC Theme Leaders

MARC's theme leader group takes on the collective responsibility for informing the strategic direction of the Monash Addiction Research Centre (MARC) and sharing information relating to MARC activities and opportunities. Theme leaders represent each of the three research themes within MARC, acting as a conduit for information between MARC and the departments and faculties in which they are based.

Science



PROFESSOR ANTONIO VERDEJO-GARCIA
Turner Institute for Brain and Mental Health



DR JENNIFER SCHUMANN
Department of Forensic Medicine



DR JENNI ILO MAKI
Centre for Medicine Use Safety



DR KATHARINA VOIGT
Turner Institute for Brain and Mental Health

Prevention and Treatment



PROFESSOR PAUL DIETZE
Burnet Institute



ASSOCIATE PROFESSOR DEBBIE SCOTT
Turning Point



PROFESSOR ARON SHLONSKY
Department of Social Work



ASSOCIATE PROFESSOR VICTORIA MANNING
Turning Point



DR SHALINI ARUNOGIRI
Turning Point



DR TINA LAM
Monash Addiction Research Centre

Culture and Policy



PROFESSOR PHILIP MENDES
Department of Social Work



DR LAURA ALFREY
School of Curriculum Teaching & Inclusive Education



ASSOCIATE PROFESSOR SONJA DE NEW
Centre for Health Economics



DR ROWAN OGEIL
Turning Point



DR MICHAEL SAVIC
Turning Point



DR FRASER TULL
BehaviourWorks

Early to Mid-Career Researcher Committee

The Centre formed an Early to Mid-Career Researcher (EMCR) sub-committee to support EMCR's, including PhD students, by offering professional support and developmental opportunities. The EMCR committee organises and attends quarterly networking events, workshops and other professional development opportunities. Our EMCR committee representatives for 2020/2021 are:



ASSOCIATE PROFESSOR SUZANNE NIELSEN
Monash Addiction Research Centre



DR TINA LAM
Monash Addiction Research Centre



DR ROWAN OGEIL
Turning Point



DR LIZ STURGISS
Department of General Practice



DR KATHARINA VOIGT
Turner Institute for Brain and Mental Health



DR JENNI ILO MAKI
Centre for Medicine Use Safety



MARC ADVISORY BOARD

MARC's external Advisory Board comprises representatives from a broad range of key stakeholders and partners who bring together a wealth of leadership and expertise. The board assists MARC in its mission to provide national solutions to the problems of addiction by increasing the visibility of the Centre across the community and supporting the work of our members.

Chair

Mietta Gibson has a commerce degree from Deakin University and has had a successful career in Human Resources for companies such as Daimler, Fiat Chrysler, World Vision and MYOB. In recent years, Mieta has been working as a consultant along with leaders and teams at a variety of organisations to create positive and inspiring workplaces.

Ms Gibson has been fortunate to have been involved with the Gibson Family foundation, a small foundation interested in creating impact in areas such as mental health. She coordinated support from the foundation to Turning Point and MARC to create video stories documenting the lived experience of people with addiction.

Being chair of the MARC Advisory Board is a great opportunity for Mieta to combine her professional experience, her lived experience of having a family member with addiction and mental health issues, and to represent her Mornington Peninsula community.



MIETTA GIBSON
Chair

Board Members

BETH ALLEN

Acting Director, Children & Families Policy Branch, Children and Families Division, Victorian Department of Health and Human Services

SAM BIONDO

Executive Officer, Victorian Alcohol and Drugs Association

ADJUNCT ASSOCIATE PROFESSOR

CHRISTOPHER CARTER CEO,
North Western Melbourne Primary Health Network (NWMPHN)

PROFESSOR DAVID COPOLOV AO

Pro Vice-Chancellor (Major Campuses and Student Engagement), Monash University

PROFESSOR KIM CORNISH

(SIR JOHN MONASH DISTINGUISHED PROFESSOR)

Director, Turner Institute for Brain and Mental Health

ASSOCIATE PROFESSOR TONY WALKER

CEO, Ambulance Victoria

AC GLENN WEIR

Assistant Commissioner, Eastern Region, Victoria Police

MELISSA ARDUCA

Director, Alcohol and Other Drugs Policy, Victorian Department of Health and Human Services

ELIZABETH DEVENY

CEO, South Eastern Melbourne Primary Health Network (SEMPHN)

ROD MACKINTOSH

Executive Officer, Frankston Mornington Peninsula Primary Care Partnership

DR ALISON DWYER

Executive Director, Research (Chief Medical Officer), Eastern Health

DICK GROSS

Councillor, City of Port Phillip

HEATHER PICKARD

CEO, Self Help Addiction Resource Centre

FELICITY TOPP

CEO, Peninsula Health

FUNDING SUCCESS



L-R Mr Hugh Piercy, A/Prof Victoria Manning & Dr Joshua Garfield

MARC researchers have been awarded more than \$9 million in research funding to conduct research relating to addiction, substance use and related behaviours. The below examples of funding success demonstrate the strength of interdisciplinary collaboration amongst our members.

SWiPE away the booze - a novel brain-training smartphone app to reduce alcohol consumption

Investigators: A/Prof Victoria Manning, Prof Dan Lubman, Dr Joshua Garfield, and Mr Hugh Piercy.

Eighteen percent of Australians aged 18 and over drink at hazardous levels, whilst one in five will experience an alcohol use disorder. Exposure to alcohol-related cues (such as images, sounds and advertisements featuring alcohol) is known to induce cravings which can lead to further alcohol use. This poses a particular challenge for individuals trying to cut-down or abstain, as alcohol-related cues are largely unavoidable in Australian society. These alcohol-related cues can subconsciously capture our attention and motivate us to seek, and subsequently consume alcohol, and this tendency is called a 'Cognitive Bias'.

Research shows that a form of computerised "brain-training" called Cognitive Bias Modification (CBM) can reduce these impulses and reduce the likelihood of alcohol consumption after just four 15-minute training sessions. However, this intervention is currently only offered in face-to-face treatment, and so is inaccessible to the thousands of Australians who choose not to, or are unable to access face-to-face treatment.

To address this gap, Turning Point researchers developed "SWiPE", a new smartphone app which aims to deliver personalised-CBM freely to users across Australia, regardless of time or place. The open-label pilot study recruited 500 people who wanted to reduce their drinking, to study whether SWiPE was feasible, acceptable to users, and whether it helped people drink less alcohol and on fewer days. Participants completed at least two sessions of CBM each week for four weeks by repeatedly 'swiping away' pictures of specific alcoholic beverages they wanted to avoid drinking, and swiping images towards themselves that represented positive alternative activities they wanted to engage in more frequently (e.g., hobbies, recreational activities, friends, family, pets, etc.). The development of a personalised, smartphone-delivered CBM app is a world-first and holds the potential to benefit the many thousands of Australians who consume alcohol at hazardous levels. Given its low-cost and scalability, SWiPE has the potential to offer a convenient, anonymous and readily available tool to help reduce alcohol cravings and consumption at times when individuals need it most.

This project is funded by the Australian Rechabite Foundation and the Alcohol and Drug Research Innovation Agenda (ADRIA).

Publications: Manning V., Piercy H., Garfield J., Lubman DI. (2020). [Personalized Approach Bias Modification Smartphone App \("SWiPE"\) to Reduce Alcohol Use Among People Drinking at Hazardous or Harmful Levels: Protocol for an Open-Label Feasibility Study. JMIR Res Protoc 2020;9\(8\):e21278.](#)

Alcohol consumption practices during COVID-19

Investigators: Dr Michael Savic, A/Prof Steven Roberts, Dr Karla Elliott, Dr Brady Robards, Dr Robyn Dwyer, Dr Tristan Duncan, Lily Curtis.

Environmental, health and financial crises faced by countries like Australia are anticipated to grow. In addition to health effects, crises, such as the global coronavirus pandemic (COVID-19), can transform common social and cultural practices like alcohol consumption.

Important measures to prevent the transmission of COVID-19, like physical distancing and self-isolation, have had profound implications for people's ability to meet socially, and for employment, care, and mental health. The potential impacts of the pandemic raise questions of pressing national and international significance about likely changes in how, why, and where people consume alcohol.

Research conducted to date has measured changes in alcohol consumption rates and harms during the COVID-19 pandemic. Building on this useful work, the current project will take an in-depth look at alcohol consumption practices in Australia and will share insights about the social and cultural impacts of the pandemic by providing practical recommendations that will contribute to new and improved policy responses during and beyond the crisis.

The team of Monash University, Turning Point and La Trobe University researchers will use qualitative research methods, including analysing participants' social media timelines, to understand meanings and practices of alcohol consumption during the pandemic and as restrictions have eased.

This project is funded by the Australian Research Council (ARC) under the Special Research Initiative for Australian Society, History and Culture.



Enabling evidence-informed policy to address Australia's opioid crisis

Investigators: A/Prof Suzanne Nielsen, Prof Simon Bell, Prof Grant Russell, Samanta Lalic, Paul Sanfilippo, Dr Georgia Richards, Prof Dan Lubman.

Australia has seen a near doubling of opioid-related mortality in the past decade. Three Australians die every day from opioids and most of these deaths are linked to prescription opioids. Recently, a range of state and national policy changes have been made to address the growing number of opioid-related deaths.

There is little evidence to know if and how these policy levers work. From international research we know that commonly implemented opioid policy interventions can be ineffective, or worse, can cause harm, yet we have limited Australian data to understand outcomes. This knowledge gap must be bridged to know if policy changes will address or worsen Australia's looming opioid crisis. This project will generate high quality Australian-specific evidence to address these gaps using the internationally unique Population Level Analyses and Reporting tool (POLAR) primary care dataset linked in near-real time to hospital outcome data to quickly understand policy impact.

The project aims to determine the effect of policy change on: (i) opioid prescribing; (ii) opioid-related harm; and (iii) harms from other substance use/ transition to illicit opioid use.

The project will link primary care and hospital data to examine the impacts of these policy changes on opioid prescribing, opioid-related harm, and other unintended harm following key policy changes to provide policy makers and clinicians with timely evidence of the impact of opioid-related policy on prescribing and harms. The project represents a collaboration between MARC, the Centre for Medicine Use and Safety and the Monash University Department of General Practice.

This project is funded by a National Health and Medical Research Council (NHMRC) Ideas Grant.





National Ambulance Surveillance System - Alcohol and Other Drugs

Investigators: Prof Dan Lubman, A/Prof Debbie Scott, Dr Rowan Ogeil.

Turning Point provides the Australian Institute of Health Welfare (AIHW) with comprehensive and timely data on AOD-related harms in the Australian population. Clinical records from state and territory-based ambulance services are provided to Turning Point in an electronic format.

A team of specially trained research assistants scrutinise and code each record, capturing the information in a purpose-built and internationally unique database. The research assistants have on-going coding training, and coding audits are performed routinely to ensure inter- and intra-coder reliability.

The data captures more than 140 variables including information on patient demographics, scene details (e.g. date of attendance, time of attendance, police co-attendance, GPS coordinates where available, postcode), patient physical condition (vital signs, patient outcome (e.g. transported to hospital), 13 illicit drugs, 82 pharmaceutical medications, other substances (including alcohol or inhalants) and intent. This data forms the basis of a novel surveillance system that identifies AOD related harms, and is subsequently used to inform policy and interventions.

This project is funded by the Australian Institute of Health and Welfare (AIHW).

Publications: Ogeil, RP, Scott, D, Faulkner, A, Wilson, J, Beard, N, Smith, K, Manning, V & Lubman, DI. (2021). *Changes in alcohol intoxication-related ambulance attendances during COVID-19: How have government announcements and policies affected ambulance call outs?*. *The Lancet Regional Health - Western Pacific*, 14, 100222.

Nielsen, S, Sanfilippo, PG, Scott, D, Lam, T, Smith, K & Lubman, DI. (2021). *Characteristics of oxycodone-related ambulance attendances: analysis of temporal trends and the effect of reformulation in Victoria, Australia from 2013 to 2018*. *Addiction*, 116(8), 2233-2241.

Lubman DI, Matthews S, Heilbronn C, Killian JJ, Ogeil RP, Lloyd B, Witt K, Crossin R, Smith K, Bosley E, Carney R, Wilson A, Eastham M Keene T, Shipp C & Scott D. (2020). *The National Ambulance Surveillance System: A novel method for monitoring acute alcohol, illicit and pharmaceutical drug related-harms using coded Australian ambulance clinical records*. *PLoS ONE*, 15(1): e0228316.

MMP-1: MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder

Investigators: Dr Paul Liknaitzky, Prof Suresh Sundram, Prof Murat Yucel (2020-2023).

Post-Traumatic Stress Disorder (PTSD) is a debilitating condition linked to substantial distress, low quality of life, and increased suicidality, with a lifetime prevalence of about 12% in Australia. Given the chronicity of PTSD, high rates of treatment dropout, and limited recovery with current medications, a large proportion of PTSD patients do not have adequate treatment options. The combined neurobiological effects of 3,4-methylenedioxymethamphetamine (MDMA) induce feelings of trust, positive mood, and elevated psychotherapeutic engagement can provide optimal conditions for conducting interventions that may otherwise prove too overwhelming for individuals suffering from trauma. MDMA in combination with psychotherapy has been shown to be safe and highly effective for treating intractable PTSD.

This open-label trial with 25 participants will examine the safety and efficacy of MDMA-assisted psychotherapy for treating PTSD in an Australian cohort, alongside innovations in assessing treatment mechanism and response prediction. Participants will undergo three MDMA-sessions embedded within a defined program of psychotherapy. Led by the Clinical Psychedelic Research Lab within the Department of Psychiatry and the Turner Institute, this trial will be conducted at BrainPark, a state-of-the-art research facility at Monash University.

This project is funded by the generous philanthropic support from Dr Nigel Strauss and the Multidisciplinary Association for Psychedelic Studies (MAPS)

Mapping the Alcohol and Other Drug patient journey to improve treatment access and engagement in care

Investigators: A/Prof Suzanne Nielsen, Dr Tina Lam, Kirsty Morgan, Dr Michael Savic, Heather Pickard, A/Prof Lisa Kuhn, Dr Nadine Andrew, Rob White, Katherine Bendall, Greer Watkins, Prof Dan Lubman (2021-2021).

Alcohol and other drugs (AOD) are involved in 137,000 Australian hospital admissions and 28% of ED injuries. This harm is preventable. Understanding patients' journeys through health systems can inform more effective delivery of evidence-based treatments. We will use novel approaches to combine big data and qualitative methods, including graphical journey mapping, to comprehensively document the patient journey to identify opportunities for increasing connection to, and retention in AOD care. Findings will inform the implementation and evaluation of targeted interventions to drive changed practice, which can reduce AOD harm for individuals, and reduce related costs for the healthcare system.

This project is funded by the National Centre for Healthy Ageing - Living Labs Program.

Determining the impacts of COVID-19 restrictions on people who use drugs

Investigators: Prof Paul Dietze, Prof Lisa Maher, Prof Matthew Hickman, A/Prof Joseph Doyle, Prof Mark Stooze, A/ Prof Bernadette Ward, Dr Keith Sutton, Dr Anna Wilkinson, Dr Brendan Quinn.

Most published work on the impacts of COVID-19 on patterns of drug use relies on information collected from cross-sectional studies of convenience samples of people who use drugs. In this study we take advantage of the SuperMIX and VMAX cohort studies of people who inject drugs and people who smoke methamphetamine, both of which recruited samples before the COVID-19 pandemic, to determine the impacts of COVID-19 on patterns of drug use and harm in Victoria.

We are also sampling key cohort members who have experienced impacts of lockdowns and associated restrictions for in-depth qualitative interviews about the effects of these restrictions on their lives. Preliminary analyses show major impacts on drug prices that correspond with reductions in use during the extended lockdown in Melbourne in 2020.

This project is funded by the National Health and Medical Research Council (NHMRC)

CURRENT RESEARCH

Envision Goals: Day 1

Goal Distractors

Beginning to recognise what distracts you from achieving your goals is important for knowing when to use PAUSE, but it is also helpful to plan for when these situations arise.

1. Write your biggest goal distractors in the billboards below.
2. In the boxes below each billboard, think on how or why they arise.
3. Then think about some ways to avoid or plan for them.
4. Look at the example to the right to help you get started.

Example: Lose motivation

How and when do these distractors tend to occur? After a bad day, I can't get motivated.

What are some ways to avoid or plan for the distractor? I can practice my DFT. I can remember good qualities about myself.

How much did you improve at refreshing your goal today? (1-10 scale)

Did today's activities help you towards reaching your goals? (A little bit, Yes, heaps! scale)

A sample page from the GMT+ workbook for program participants to use during and after their training.

Below are some highlights of the addiction-related research completed by our members in the 2020/2021 year.

Development of Goal Management Training+ (GMT+) for methamphetamine use disorder through collaborative design

Investigators: Alexandra Anderson, Alex Robinson, Eden Potter, Bronte Kerley, Prof Daphne Flynn, Prof Dan Lubman, Prof Antonio Verdejo-Garcia.

Current gold-standard behavioural treatments for stimulant use disorders do not address executive dysfunctions that are associated with poorer treatment outcomes, and have limited acceptability and efficacy. This project, led by MARC member Antonio Verdejo-Garcia, employed a collaborative design approach to tailor Goal Management Training (GMT), a cognitive remediation program originally designed for brain injury, for methamphetamine use disorder (MUD). We collaborated with consumers living with MUD, clinical service providers, and design researchers in healthcare.

The end product, GMT+, is a four-week group-based program that targets four underlying cognitive processes, including attention, impulse control, goal setting, and decision-making. It includes reimagined design and materials, is sensitive to the clinical needs of consumers, and has evidence of initial consumer acceptability. We are currently conducting a pilot trial to assess the feasibility and efficacy of GMT+ at improving executive functions and clinical outcomes during residential treatment for MUD.

This project was funded by the National Centre for Clinical Research on Emerging Drugs (NCCRED) and the Monash Addiction Research Centre (MARC).

Publications: Anderson, AC., Robinson, AH., Potter, E., Kerley, B., Flynn, D., Lubman, DI., Verdejo-Garcia, A. (2021). Development of Goal Management Training+ (GMT+) for Methamphetamine Use Disorder through collaborative design: A process description. *medRxiv* 21261454 (Preprint).

Anderson, AC., Youssef, GJ., Robinson, AH., Lubman, DI., & Verdejo-Garcia, A. (2021). Cognitive boosting interventions for impulsivity in addiction: a systematic review and meta-analysis of cognitive training, remediation and pharmacological enhancement. *Addiction*, 116(12), 3304-3319.

Understanding the rates and characteristics of Victorian emergency department attendances for commonly used pharmaceutical opioids

Investigators: A/Prof Suzanne Nielsen, Dr Tina Lam, Prof Dan Lubman

Pharmaceutical opioids are a significant contributor to the global 'opioid crisis', yet few studies have comprehensively distinguished between opioid types. We measured whether a range of common pharmaceutical opioids varied in their contribution to the rates and characteristics of harm in a population-wide indicator of non-fatal overdose.

This retrospective observational study examined Emergency Department (ED) patient care records in the Victorian Emergency Minimum Dataset (VEMD) between July 2009 and June 2019. ED presentations were for non-fatal overdose related to pharmaceutical opioid use (n=5403), where the specific pharmaceutical opioid was documented.

We compared harms across the nine individual pharmaceutical opioids most commonly sold and found there were up to 27 fold, between supply-adjusted rates of overdose. The highest supply-adjusted overdose rates were for codeine and oxycodone and the lowest were for tapentadol and fentanyl. These rates appeared related to availability rather than opioid potency. We found variations in presentation characteristics such as self-harm and severity of presentation by gender and age.

In summary, we found that in Victoria, rates and characteristics of emergency department presentations for pharmaceutical opioids show distinct variations by opioid type.

This study was funded by an untied educational grant from Seqirus (CSL)

Publications: Lam, T., Hayman, J., Berecki-Gisolf, J., Sanfilippo, P., Lubman, DI., & Nielsen, S. (2020). Comparing rates and characteristics of emergency department presentations related to pharmaceutical opioid poisoning in Australia: a study protocol for a retrospective observational study. *BMJ Open*, 10, e038979.

Lam, T., Hayman, J., Berecki-Gisolf, J., Sanfilippo, P., Lubman, D. I. & Nielsen, S. (2021). Pharmaceutical opioid poisonings in Victoria, Australia: Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids. *Addiction*, 117(3), 623-636.





A randomised controlled trial of Cognitive Bias Modification training during early recovery from alcohol dependence

Investigators: A/Prof Victoria Manning, Prof Antonio Verdejo-Garcia, Prof Dan Lubman, Dr Petra Staiger, Dr Kate Hall (2017-2020).


This cognitive bias modification (CBM) research project aimed to test whether four short sessions of “brain-training”, using a laptop and joystick and delivered while clients are in residential withdrawal treatment (i.e., “detoxification”), helps people avoid relapse to alcohol use after discharge from treatment. The majority of people relapse to alcohol use after leaving withdrawal treatment, usually within a few weeks. One potential reason for this is that many people with an alcohol use disorder appear to develop “approach bias” towards alcohol, meaning an automatic tendency to approach alcohol in response to signals (such as images, smells, etc.) that remind them of alcohol. This “approach bias” might not be fully under one’s conscious control.

Our randomised controlled trial (RCT) compared a computerised CBM training task designed to dampen approach bias to another similar task that used the same images and equipment, but which was not specifically designed to change approach bias, to see whether the CBM task leads to higher rates of abstinence from alcohol after people leave residential withdrawal treatment. We recruited 300 participants from four residential withdrawal units around Melbourne from 2017-2019. We followed up participants two weeks, three months, six months, and one year after they left withdrawal treatment.

This project was funded by the National Health and Medical Research Council (NHMRC).

Publications: Manning, V., Garfield, JBB., Campbell, S., Reynolds, J., Staiger, P. K., Lum, JAG., Hall, K., Wiers, R. W., Lubman, D. I., & Verdejo-Garcia, A. (2018). Protocol for a randomised controlled trial of cognitive bias modification training during inpatient withdrawal from alcohol use disorder. *Trials*, 19, 598.

Manning, V., Garfield, JBB., Staiger, PK., **Lubman, DI.,** Lum, JAG., Reynolds, J., Hall, K., Bonomo, Y., Lloyd-Jones, M., Wiers, RW., Piercy, H., Jacka, D., **Verdejo-Garcia, A.** (2021). Effect of Cognitive Bias Modification on early relapse among adults undergoing inpatient alcohol withdrawal treatment: a randomized clinical trial. *JAMA Psychiatry*; 78: 133-140.



The R2C Program: A randomised controlled trial of a telephone-based intervention for alcohol misuse

Investigators: Prof Dan Lubman, Prof Amanda Baker, Prof Petra Staiger, Prof David Best, A/Prof Victoria Manning, Dr Kate Hall, A/Prof John Reynolds, Prof Anthony Harris, Dr Jasmin Grigg.

Alcohol use and related harm is a significant issue for many Australians. However, few people seek help from traditional alcohol and other drug treatment services due to concerns about privacy, experiences of shame and stigma, time constraints (e.g. due to work or child care responsibilities), or thinking the problem isn’t serious enough to warrant conventional treatment. Many barriers to seeking help for alcohol use problems can be overcome through treatment programs that are delivered by telephone. These programs provide confidential support, at times convenient to the individual, and can be accessed from anywhere in Australia, though research evidence is limited to services delivering support to aid smoking cessation. This trial aimed to determine the efficacy of the Ready2Change (R2C) telephone-delivered intervention in reducing alcohol problem severity among a community sample of individuals with alcohol use problems.

In this double-blind RCT, 344 participants identified as experiencing alcohol problems in the community were randomly assigned to receive R2C or another brief intervention (i.e. minimal input control group), with follow-ups assessing alcohol use, and psychological health assessed post-intervention, 3, 6 and 12 months later.

The outcomes of this project are expected to make a significant contribution to the health and well-being of Australians who are otherwise unlikely to seek treatment from traditional alcohol and other drug treatment services, as well as generate substantial cost savings for the health system and broader community.

This project was funded by the National Health and Medical Research Council (NHMRC).

Publications: Lubman, D., Grigg, J., Manning, V., Hall, K., Volpe, I., Dias, S., Baker, A., Staiger, P., Reynolds, J., Harris, A., Tyler, J and Best, D. (2019). Ready2Change: A randomised controlled trial of a structured telephone-delivered intervention to reduce problem alcohol use. *Trials*, 20, 515.

Bernard, C., Grigg, J., Volpe, I., Lubman, DI., & Manning, V. (2020). Client experiences of a telephone-delivered intervention for alcohol use: a qualitative study. *International Journal of Mental Health and Addiction*, 20, 522-540.

Women's Voice: A platform for meaningful consumer representation in addiction treatment for women at risk of homelessness

Investigators: Dr Shalini Arunogiri, Ms Davinia Rizzo

Women’s Voice is a consumer-focused project, aiming to understand the perspectives of women with a lived experience of addiction and homelessness, and their experiences in accessing addiction treatment. The project was conducted between 2019-2021 and involved focus groups and stakeholder interviews with consumers and key service providers across Melbourne. The project also utilised live scribing to develop a graphic record of the main themes expressed by consumers in qualitative focus groups. The project provided insights into how to develop a useful and meaningful platform for consumer feedback for women living with addiction and homelessness.

This project was funded by the Victorian Women's Trust - Jean McCaughey Social Justice sub fund.



Investigating influence: an analysis of Australian 'dangerous consumption' research funding and outcomes

Investigators: A/Prof Charles Livingstone, Maggie Johnson, Cassandra de Lacy-Vawdon.

This project investigated the extent to which significant gambling industry actors are also major political donors. There are serious deficiencies in the Australian system of recording and reporting Australian political donations and donors, particularly at the Federal level. Thus, voters rarely have the opportunity to know what entities or interests have donated to political parties until at least 18 months after donations have been made. Further, donations below a high threshold (currently over \$14,500) do not have to be disclosed.

This project examined available records to compile a list of donations and presented case studies identifying specific instances of close political engagement by gambling industry actors, together with some temporal correlation of political decisions. This project has been running for some time as a continuing research project of significant public interest under the broad banner of 'Gambling industry influence'.

Publications: Johnson, M., & Livingstone, C. (2021). *Measuring influence: an analysis of Australian gambling industry political donations and policy decisions*. *Addiction Research & Theory*, 29(3), 196-204.

Livingstone, C., & Johnson, M. (2017) 'Gambling lobby gives big to political parties, and names names'. *The Conversation*.

The MonCOG Project: Validating a neurocognitive framework for addictive behaviours

Investigators: Prof Murat Yucel, Dr Rico Lee, Dr Sam Chamberlain.

The cognitive neuroscience of addictive behaviours has been hampered by a convoluted landscape of neurocognitive functions and definitions, as well as a predominant focus on cross-sectional convenience sampling. This NHMRC project grant-funded study recruited a large, population-representative Australian sample (N=1,000) to shed light on the unique and shared contributions of a range of NIMH-RDoC constructs to addiction-related outcomes. A further MRFF investigator grant funded the follow-up of a subset of young adults aged 18-34 re-assessed prospectively over six months to allow for modelling of temporal relationships. Sophisticated structural equation modeling and machine learning techniques will be utilised to derive a more accurate understanding of how we can best measure neurocognition and how these constructs are mechanistically linked to addiction-related outcomes in the general community. Data collected from these studies will also contribute to a living, normative database sitting behind a purpose-built digital assessment tool at BrainPark.

This project is jointly funded by the National Health and Medical Research Council (NHMRC) and the Medical Research Future Fund (MRFF).

Publications: Albertella, L., Rotaru, K., Christensen, E., Lowe, A., Brierley, M. E., Richardson, K., Chamberlain, S. R., Lee, R. S. C., Kayayan, E., Grant, J. E., Schluter-Hughes, S., Ince, C., Fontenelle, L. F., Segrave, R. & Yücel, M. (2021). *The influence of trait compulsivity and impulsivity on addictive and compulsive behaviors during COVID-19*. *Frontiers in Psychiatry*, 12, 162.

Den Ouden, L., Tiego, J., Lee, R. S. C., Albertella, L., Greenwood, L-M., Fontenelle, L., Yücel, M. & Segrave, R. (2020). *The role of Experiential Avoidance in transdiagnostic compulsive behavior: A structural model analysis*. *Addictive Behaviors*, 108(8), 106464.

The politics of the Medically Supervised Injecting Room debate

Investigator: Prof. Philip Mendes

This project analysed the political and ideological factors impacting on the supervised injecting facility debate in Victoria, including the role of political parties, the views of the media, the perspectives of local community groups, and the impact of other supportive and critical stakeholders.

It seems that policy agendas and outcomes have been influenced by a range of factors including philosophical contests between prohibitionist and harm reduction philosophy, varied beliefs in the value of research evidence, a mixture of political expediency, populism and principled politics, and the influence of local community advocacy campaigns.

Publications: Mendes, P. (2021). *Putting prohibitionist philosophy and populism before evidence on illicit drugs: Why has the Victorian Liberal-National Party Coalition opposed Supervised Injecting Facilities for two decades?* *Australian Journal of Social Issues*.

Mendes, P. (2021). *How does politics impact on illicit drug policy in Australia? A case study of the Victorian Labor Party and the Medically Supervised Injecting Room (MSIR)*. *Monash Lens*.



THOUGHT LEADERSHIP



As experts in their field, MARC members regularly contribute thought leadership pieces for the leading publisher of research-based news and analysis, *The Conversation*, and Monash University's thought leadership platform, *Lens*.

Reassessing the social context of illicit drug use and addiction - *Monash Lens*

Prof Philip Mendes

In Australia, a survey conducted at Sydney's King's Cross injecting facility reported 96 percent of regular users had a history of trauma, with users often seeing drug use as a solution to deep-seated social, economic, and emotional problems. Research led by Professor Philip Mendes found problematic substance use is particularly apparent in two disadvantaged population groups: young people transitioning from out-of-home care; and Australians of working age on unemployment payments, with the latter being subject to conditional welfare such as compulsory income management. Despite key assumptions by government that income management programs will reduce forms of individual and community harm associated with alcohol and other (AOD) use, Professor Mendes' study highlights that IM doesn't address the complex underlying social, psychological and medical causes of AOD use, or the many complex factors involved in pathways to addiction management or abstinence. While structural solutions to illicit drug use may offer some answers, addressing the underlying emotional or psychological affliction that leads to drug dependence is crucial. [Read more](#)

Youth anxiety and depression are at record levels. Mental health hubs could be the answer - *The Conversation*

Dr Christine Grove

In response to the ongoing decline in young people's mental health and the growing number of young people presenting at emergency rooms due to a lack of other treatment options, the Royal Commission into Victoria's Mental Health System adopted recommendations to implement youth mental health hubs, some of which will soon be rolled out in priority areas across the state. Youth mental health hubs provide mental health and social services in one location and have a range of specialists on site, such as trained mental health clinicians, sexual health support counsellors and psychiatrists. The hubs are co-designed by experts and youth with lived experience, on equal grounds, and are a youth friendly, one-stop-shop for support ranging from referrals, assessment, therapies and intervention. Dr Christine Grove says that while having all services in one location works well, it doesn't necessarily mean a coordinated, collaborative approach to care is provided. If we are to ensure more young people access the care they need, greater investment is needed to improve existing hubs or co-design new ones. [Read more](#)

Opioids continue to be the leading cause of overdose deaths in Australia. What else can we do? - *The Conversation*

Dr Amanda Roxburgh, Prof Paul Dietze, A/Prof Suzanne Nielsen

Opioid-related deaths in Australia have been on an upward trend in recent years, having doubled since 2006. Most opioid deaths in Australia involve pharmaceutical opioids, though heroin deaths have increased over the past five years. Among all opioid deaths, just over half of people overdosing have a history of injecting drugs and substance use problems. However, a large driver of increasing opioid deaths here and internationally has been the increase in prescribing and use of pharmaceutical opioids. Australia has introduced a range of strategies to manage and restrict supply, and one key response has been to provide opioid agonist treatment. Yet because of barriers to treatment, only around half take up this treatment. MARC'S Dr Amanda Roxburgh, A/Prof Suzanne Nielsen and Prof Paul Dietze say we need to double treatment capacity to meet the demand for people who may benefit from opioid agonist treatment. [Read more](#)

A mental disorder, not a personal failure: why now is the time for Australia to rethink addiction - *The Conversation*

Prof Dan Lubman AM

In simple terms, addiction is the inability to stop consuming a drug or cease an activity, even if it's causing physical or psychological harm. A common misconception is that addiction is the result of a lack of willpower or poor self-control. But in reality, it is a complex health disorder with a range of biological, developmental and environmental risk factors, including trauma, social isolation or exclusion, and genetics. Around one in four Australians will develop an alcohol, drug or gambling disorder during their lifetime, and around one in 20 will develop addiction, the most severe form of the disorder. Across Australia, treatment for addiction remains fragmented, with limited opportunities for ongoing care, no national plan, and limited opportunities for specialist addiction training. This is in stark contrast with other chronic health conditions where there are clear training pathways, clinical guidelines and national models of care. Prof Dan Lubman AM says treating addiction like any other health disorder has to start with strong public policy reform and intervention to ensure the health system is adequately supported and resourced, so accessible and timely treatment is available to people who need it.

"Until we change how we view addiction — from personal failure to a mental disorder, something we cannot control any more than we can control cancer — Australians, and millions globally, will continue to suffer." [Read more.](#)

Will Australia legalise ecstasy and magic mushrooms to treat mental illness? Here's why it's still too soon - *The Conversation*

Dr Martin Williams

The Therapeutic Goods Administration (TGA) evaluates a range of proposals around the provision of medical treatments in Australia, one of which is the decision to allow psychiatrists to prescribe MDMA and psilocybin to treat mental illness. The TGA has deferred its final decision to down-schedule MDMA and psilocybin to a schedule 8 (controlled drug) pending a review into the therapeutic value, risks and benefits to public health outcomes for these substances, however psychedelic drugs for the treatment of mental illness does represent a promising area and any new treatment which could help people suffering. According to Dr Martin Williams, until Australia engages in further research into the therapeutic potential of these drugs, it is too soon to make them available as medicines. [Read more](#)

Read more thought leadership pieces from MARC members below.

[People who use drugs face unique challenges under hard lockdown. The government's support is vital - *The Conversation*](#)
A/Prof Suzanne Nielsen

[The uncomfortable truth about drug overdose and suicide - *Monash Lens*](#)
Prof Dan Lubman, A/Prof Suzanne Nielsen, A/Prof Debbie Scott

[How a simple brain training program could help you stay away from alcohol - *The Conversation*](#)
A/Prof Victoria Manning

[Reducing problem drinking by training the subconscious brain - *Monash Lens*](#)
A/Prof Victoria Manning, Prof Antonio Verdejo-Garcia, Prof Dan Lubman

[If Crown is unfit to hold a Sydney casino licence, what about Melbourne, and Perth? - *The Conversation*](#)
A/Prof Charles Livingstone

[Happier 21st? Victoria's out of home care comes of age - *Monash Lens*](#)
Prof Philip Mendes

[Melbourne finally has a Crown royal commission- is this going to stop crime and gambling harm? - *The Conversation*](#)
A/Prof Charles Livingstone

[Responsible gambling — a bright shining lie Crown Resorts and others can no longer hide behind - *The Conversation*](#)
A/Prof Charles Livingstone

KEY ACTIVITIES

Building addiction research capacity

- Delivered 10 interdisciplinary webinars attracting over 2000 registrations.
- Delivered quarterly EMCR workshops, including social media, data linkage, productive writing techniques, and science communication.
- Established the MARC PhD network.
- Recruitment of a Research Fellow and two Research Officers

MARC interdisciplinary webinar series

Since August last year, MARC has delivered 10 webinars in its interdisciplinary series, showcasing 25 MARC researchers, one international guest speaker, and attracting over 2000 registrations. In addition, we established the Monash Addiction Research Centre YouTube channel which houses all of our webinars and provides audiences with ongoing access to the series. We have received several requests from external stakeholders to use the recordings as part of their professional development materials.

EMCR events

MARC has continued to offer professional development opportunities for our EMCRs, delivering four online workshops over the past 12 months covering social media, data linkage, productive writing techniques and science communication.

PhD network

The MARC PhD network brings together Monash PhD students from various disciplines, departments, and faculties interested in or currently undertaking addiction-related research. Chaired by Louisa Picco, and co-chaired by Helena Cangadis-Douglass and Monica Jung, the network connects students researching similar areas, encourages collaboration, promotes students' work, and provides opportunities to participate in addiction-related research events, professional development, workshops, and networking opportunities.

Building our team

In July 2020, Dr Ali Cheetham joined MARC as Research Officer working on the 'Enhancing Pharmacist Involvement in Care in Medically Assisted Treatment for Opioid Dependence' (EPIC-MATOD). In May 2021, we welcomed Dr Leanne Francia as Research Officer working on the 'Mapping the Alcohol and other Drug Patient Journey' project, and Dr Ting Xia as Research Fellow working on the NHMRC funded project using linked primary care and hospital data to examine the impact of changing opioid policy on opioid prescribing and opioid-related harms.

MARC PHD STUDENTS


The Monash Addiction Research Centre funds PhD scholarships, including top-up scholarships for students undertaking addiction research. Our current PhD funded students and top-up scholars are:

PhD Scholarships



Helena Cangadis-Douglass

'Utilising routinely collected primary health care data to understand prescribing trajectories of opioids'



Monica Jung

'Utilising primary health care data to understand and optimise prescribing of drugs of dependence'

PhD Top-up Scholars



Michael Curtis

'Understanding the impact of opioid substitution therapy programs on drug use, health service utilisation, morbidity and mortality among young people who inject drugs following release from prison'



Louisa Picco

'Implementation of prescription drug monitoring programs: Measuring the intended and unintended outcomes of identifying high-risk opioid use'



Dr Pallavi Prathivadi

'Improving opioid prescribing in Australian general practice'

EHCS Scholarship Students

MARC welcomed three Eastern Health Clinical School Scholarship (EHCS) students; medical students Lucas Neumaier, Surina Butler and Rachel Niesen. Lucas, Surina and Rachel worked on a systematic review project titled 'Do we need tailored opioid prevention strategies for women?' The project investigated whether the prevalence and characteristics of fatal and non-fatal opioid overdoses differ for women, and looked to identify subpopulations with an increased risk or unique needs. The project team also included A/Prof Suzanne Nielsen, Dr Tina Lam, Louisa Picco, Dr Leanne Francia, Dr Anna Olsen and Wai Chung Tse.



POLICY

MARC submission to the Australian Commission on Safety and Quality in Health Care - National Opioid Analgesic Stewardship Program

In collaboration with Peninsula Health and the Centre for Medicine Use and Safety, MARC members made a submission to the Australian Commission on Safety and Quality in Health Care to inform the development of the National Opioid Analgesic Stewardship Program. The submission was informed by collaborative work between MARC and Peninsula Health on Opioid stewardship and work by CMUS PhD Candidate Laura Dowd and Professor Simon Bell, who have looked at opioid stewardship in long-term care facilities.

The submission provided feedback on a discussion paper drafted to support public consultation on the use of opioid analgesics in emergency departments, perioperative and surgical services. The Commission is also interested in learning more about education and training for prescribers of opioid analgesics. Read the full discussion paper [here](#)

Release of the Royal Commission's final report into Victoria's Mental Health System

March 2, 2021 was a momentous day for mental health in Victoria with the final report of the Royal Commission into Victoria's Mental Health System handed down at a special sitting of the Victorian Parliament at the Royal Exhibition Building. The final report outlined 65 recommendations, with nine recommendations from the interim report.

MARC welcomed all of the recommendations, including those that support improving outcomes for people living with mental illness and substance use or addiction. Of the recommendations is the provision for dedicated research, education and training, and a priority to increase the number of addiction specialists in Victoria.

MARC Director, Professor Dan Lubman, attended the sitting, saying: "It was wonderful to see the Government's commitment to deliver on all of the recommendations outlined in the report, and it's exciting for what can be achieved together moving forward."

MARC member, Dr Melissa Petrakis, was also in attendance in her capacity as Senior Lecturer, Department of Social Work and Tandem Board Chair, representing family members and carers across Victoria, having been an expert witness to the Commission last year.

Dr Petrakis noted: "It was important to hear both sides of parliament offer bipartisan commitment to invest in mental health. Their work is to not just fill in potholes but, as Royal Commission Chair Penny Armytage AM attested, to build a new road. A lived experience led design of that road is the next step for genuine reform."

MARC presents at the Inquiry into use of Cannabis in Victoria

In April 2021, Professor Dan Lubman AM and Dr Christine Grove presented the MARC and Turning Point joint submission to the Inquiry into the Use of Cannabis in Victoria.

At a public hearing of the Victorian Parliament's Legal and Social Issues Committee, Professor Lubman and Dr Grove detailed how the submission's recommendations would help improve health outcomes. Recommendations included the need to implement public health campaigns and school-based health education programs to ensure children, young people, and adults develop critical health literacy in relation to drug use and mental health, and build their help-seeking skills.

The submission also noted the negative impacts of criminalisation and emphasised the need for improved diversion programs that adopt a public health approach to cannabis use and keep people out of the criminal justice system.



Shining light on gambling harms

The Royal Commission into the Casino Operator and Licence in Victoria has done much more than unearth the many wrongdoings of Crown Melbourne; it has presented an enormous opportunity to shed light on gambling harms.

Every day, an Australian struggling with their gambling dies by suicide. Inadequate statutory obligations, weak regulatory oversight, and a lack of services for people with gambling addiction, all contribute to this horrifying statistic.

The system is broken and in need of urgent reform.

Onus is wrongly placed on vulnerable people with gambling addiction to do what their condition prevents them from doing; that is to 'gamble responsibly'. How does one 'gamble responsibly'? The onus should instead be placed on gambling operators that at best, are failing to support, and at worst, are exploiting, vulnerable people living with addiction.

In May 2021, the Monash Addiction Research Centre together with Turning Point made a joint submission to the Royal Commission. Among its many recommendations were calls to cap the number of machines in areas of socio-economic disadvantage; development of a quality and outcomes framework and optimal care pathways for gambling disorders; and a campaign that tackles stigma and normalises help-seeking for gambling addiction.

On October 26, the landmark final report from the Royal Commission into the Casino Operator and Licence was handed down. The Victorian Government's swift introduction of legislation to appoint a Special Manager to oversee Crown's rehabilitation and establish an adequately resourced and empowered Victorian Gambling and Casino Control Commission has been welcomed.

MARC Director, Prof Dan Lubman AM, says the legislation is an important first step in reforming a broken industry and protecting vulnerable Victorians experiencing gambling harms.

"Together we can build a gambling industry not based on the proceeds of crime or the exploitation of vulnerable people and give people struggling with gambling the help and support they need and deserve," he said.

[Read the submission here.](#)



MEDIA

MARC has continued its strong media presence across various media platforms with our members regularly providing expert public commentary to mainstream media outlets including ABC News, ABC Radio, SBS News, The Guardian and The Age.

Radio, print and online media

The Age - 30 June 2020

[Poker machines used to launder cash and avoid tax](#)

Mirage News - 9 July 2020

[Distress and pain key reasons for prescription opioid abuse](#)

Australian Pharmacy - 15 July 2020

[These are the reasons people misuse prescription opioids](#)

2GB - 23 July 2020

[Crown Casino's plans to introduce EFTPOS machines at gambling tables](#)

ABC Radio National - 1 August 2020

[Wheelchair fitness, alcohol and sport](#)

AJP.com.au - 14 August 2020

[Prescription opioids: A needed discussion](#)

Nine News - 18 August 2020

[Australian casinos lost \\$14m each day during lockdown](#)

The wire - 31 August 2020

[Opioids the leading cause of overdose death in Australia](#)

Croakey - 7 October 2020

[How the gambling lobby makes a strong case for political reform](#)

ABC Radio Sydney - 12 October 2020

[The rise in profits for online gambling companies during the COVID-19 pandemic](#)

ABC News Radio - 19 October

[Crown Casino investigated over potential money laundering breaches](#)

SBS - 20 October 2020

[Ten Australians confront their addictions in a powerful new documentary series](#)

ABC Mid North Coast - 20 October 2020

[Professor Lubman explains the extent of gambling in Australia](#)

AJP.com.au - 21 October 2020

[Nuance needed opioids and harm](#)

InSight+ - 26 October 2020

[Opioid prescribing: personalised approach is way forward](#)

The Guardian - 2 November 2020

[Addiction is a chronic health condition - why isn't it treated like one?](#)

Australia Pharmacist - 4 November 2020

[Risk factors for long-term opioid misuses](#)

RRR Radiotherapy - 15 November 2020

[Discussing the new SBS documentary 'Addicted Australia'](#)

The Quicky MamaMia podcast - 16 November 2020

[Fiona O'Loughlin's battle against the drug that kills you as kick it](#)

Business News Australia - 20 November 2020

[It's hard to see how Crown resorts can be found fit and proper to run Sydney's Barangaroo casino](#)

ABC News - 30 November 2020

[How gambling authorities missed Crown's criminal ties](#)

PortNews - 4 December 2020

[Alcohol harm greatest in three life stages](#)

Health Report ABC Radio National - 7 December 2020

[Rewiring the brain to prevent alcohol relapse](#)

Mirage News - 11 December 2020

[Oxycodone-related ambulance presentations are more likely to be women and those with mental health issues](#)

The Age - 17 December 2020

[Where were the controls? Crown's performance needed closer scrutiny](#)

The Age - 10 February 2021

[Changing Crown's board is not enough. It's time for tough regulation](#)

The Age - 26 February 2021

[Dirty money fears as poker machine losses top pre-pandemic levels](#)

ABC News - 9 March 2021

[New rules for opioids leaves few options for Aussies in pain](#)

The Age - 11 March 2021

[A cheap heat pack to replace opioids for back pain? It may work](#)

Australian Financial Review - 17 March 2021

[Victorian royal commission into crown resorts starts next week](#)

Asia-Pacific Biotech News - 4 April 2021

[New Brain-Training to Prevent Alcohol Relapse](#)

ABC Radio - April 16 2020

[Discussing gambling behaviour, and how exposure to it can lead to gambling intentions and behaviours](#)

ABC Radio - 20 April 2021

[Mind-altering medicines and antivirals](#)

2GB Radio - 20 April 2021

[Deborah Knight opens up about personal stake in addiction 'conundrum'](#)

InSight - 26 April 2021

[Co-prescribing naloxone: taking the stigma out](#)

Cosmos - 26 April 2021

[Opioids and overdose risk](#)

AJP.com.au - 30 April 2021

[Pharmacists, GPs urged to co-prescribe naloxone](#)

newsGP - 30 April 2021

[Should GPs routinely prescribe naloxone to people who use opioids?](#)

The Age - 10 May 2021

['Game changer' treatment cuts heroin use](#)

Cosmos magazine - 28 May 2021

[Can games tell if you are impulsive? A new computer game can assess people's level of disinhibition](#)

The Guardian - 30 May 2021

[The psychologists signing up for psychedelic therapy training: 'Amazing things can happen'](#)

NewsGP - 3 June 2021

[How can opioid deaths be reduced?](#)

The Age - 11 June 2021

[Melbourne's first safe injecting room fulfilling its purpose research finds](#)

The Guardian - 19 June 2021

[I'm living proof how Melbourne's drug injecting room has changed and saved lives](#)

Radio 2M - 26 June 2021

[International Day Against Drug Abuse and Illicit Trafficking](#)

OUR COLLABORATORS

Members of the Monash Addiction Research Centre collaborate with a diverse range of local, national and international research and clinical partners. The agencies listed below represent some of our key partnerships with research organisations, health services and community associations.

[Alfred Health](#)

[Ambulance Victoria](#)

[Area 4 Pharmacotherapy Network](#)

[Association of Participating Service Users](#)

[Australian Institute of Family Studies](#)

[Australian National University](#)

[Australian Research Council](#)

[Barwon Health](#)

[Beyond Blue](#)

[Bouverie Centre](#)

[Burnet Institute](#)

[Cancer Council Victoria](#)

[Chisholm TAFE](#)

[Deakin University](#)

[Defence Health](#)

[Department of Health and Human Services, Victoria](#)

[Department of Health, Commonwealth](#)

[Eastern Health](#)

[Eastern Health Foundation](#)

[Eastern Melbourne PHN](#)

[Foundation for Alcohol Research and Education \(FARE\)](#)

[La Trobe University](#)

[Monash Health](#)

[Movember](#)

[National Drug and Alcohol Research Centre \(NDARC\),
University of New South Wales](#)

[National Drug Research Institute \(NDRI\), Curtin University](#)

[Nurses and Midwives Health Program Victoria](#)

[Penington Institute](#)

[Peninsula Health](#)

[Responding to Alcohol and Drugs in the Frankston and
Mornington Peninsula \(RAD-FMP\)](#)

[Self Help Addiction Resource Centre \(SHARC\)](#)

[Sheffield Hallam University, UK](#)

[St Vincent's Hospital, Melbourne](#)

[Turning Point](#)

[University of Melbourne](#)

[University of Newcastle](#)

[University of Oregon, USA](#)

[University of Queensland](#)

[University of Sydney](#)

[University of Tasmania](#)

[University of Wollongong](#)

[VicHealth](#)

[Victorian Alcohol and Drug Association \(VAADA\)](#)

[Victorian Responsible Gambling Foundation](#)

[Windana](#)

[World Health Organisation](#)

[Youth Support + Advocacy Service \(YSAS\)](#)



The NCHA has a new home within the Ngarnga Centre to house its Healthy Ageing Data Platform.

PUBLICATIONS

1. **Albertella, L**, Chamberlain, SR, Le Pelley, ME, Greenwood, L-M, Lee, RSC, Den Ouden, L, Segrave, RA, Grant, JE & Yücel, M. (2020). **Compulsivity is measurable across distinct psychiatric symptom domains and is associated with familial risk and reward-related attentional capture.** *CNS Spectrums*, 25(4), 519-526.
2. **Albertella, L**, Rotaru, K, Christensen, E, Lowe, A, Brierley, ME, Richardson, K, Chamberlain, SR, Lee, RSC, Kayayan, E, Grant, JE, Schluter-Hughes, S, Ince, C, Fontenelle, LF, **Segrave, R** & **Yücel, M**. (2021). **The influence of trait compulsivity and impulsivity on addictive and compulsive behaviors during COVID-19.** *Frontiers in Psychiatry*, 12, 634583.
3. **Albertella, L**, Vd Hooven, J, Bovens, R & Wiers, RW. (2021). **Reward-related attentional capture predicts non-abstinence during a one-month abstinence challenge.** *Addictive Behaviors*, 114, 106745.
4. Alvin M, **Picco L**, Wood P, Mnatzaganian G, & **Nielsen S**. (2020). **Community pharmacists' preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey.** *International Journal of Clinical Pharmacy*, 43(2), 411-419.
5. Amiet, D, Youssef, GJ, Hagg, LJ, Lorenzetti, V, Parkes, L, Solowij, N & **Yücel, M**. (2020). **Young Adults With Higher Motives and Expectancies of Regular Cannabis Use Show Poorer Psychosocial Functioning.** *Frontiers in Psychiatry*, 11, 599365.
6. **Anderson, AC**, Youssef, GJ, Robinson, AH, **Lubman, DI** & **Verdejo-Garcia, A**. (2021). **Cognitive boosting interventions for impulsivity in addiction: a systematic review and meta-analysis of cognitive training, remediation and pharmacological enhancement.** *Addiction*.
7. **Arunogiri, S** & Lintzeris, N. (2021). **Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.** *Journal of Substance Abuse Treatment*, 124, 108221.
8. Barber, M, Gardner, J, **Savic, M** & **Carter, A**. (2020). **Ibogaine therapy for addiction: Consumer views from online fora.** *International Journal of Drug Policy*, 83, 102857.
9. **Barnett, A**, **Savic, M**, Pienaar, K, **Carter, A**, Warren, N, Sandral, E, **Manning, V** & **Lubman, DI**. (2020). **Enacting 'more-than-human' care: Clients' and counsellors' views on the multiple affordances of chatbots in alcohol and other drug counselling.** *International Journal of Drug Policy*.
10. Beck, AK, Kelly, PJ, Deane, FP, Baker, AL, Hides, L, **Manning, V**, Shakeshaft, A, Neale, J, Kelly, JF, Gray, RM, Argent, A, McGlaughlin, R, Chao, R & Martini, M. (2021). **Developing a mHealth Routine Outcome Monitoring and Feedback App ("SMART Track") to Support Self-Management of Addictive Behaviours.** *Frontiers in Psychiatry*, 12, 677637.
11. Beck, AK, Larance, B, Deane, FP, Baker, AL, **Manning, V**, Hides, L, Shakeshaft, A, Argent, A & Kelly, PJ. (2021). **The use of Australian SMART Recovery groups by people who use methamphetamine: Analysis of routinely-collected nationwide data.** *Drug and Alcohol Dependence*, 225, 108814.
12. Beks, H, Mc Namara, KP, Manias, E, Dalton, A, Tong, E & **Dooley, M**. (2021). **Hospital pharmacists' experiences of participating in a partnered pharmacist medication charting credentialing program: a qualitative study.** *BMC Health Services Research*.
13. **Bernard, C**, **Grigg, J**, **Volpe, I**, **Lubman, DI** & **Manning, V**. (2020). **Client Experiences of a Telephone-Delivered Intervention for Alcohol Use: a Qualitative Study.** *International Journal of Mental Health and Addiction*.
14. Bishop, M, **Schumann, J**, **Gerostamoulos, D** & Wong, A. (2021). **The impact of codeine upscheduling on overdoses, Emergency Department presentations and mortality in Victoria, Australia.** *Drug and Alcohol Dependence*, 226, 108837.
15. Booth, N, Dowling, NA, Landon, J, **Lubman, DI**, Merkouris, SS & Rodda, SN. (2021). **Affected others responsivity to gambling harm: An international taxonomy of consumer-derived behaviour change techniques.** *Journal of Clinical Medicine*, 10 (4), 583, 1-21.
16. Bonevski, B, **Manning, V**, Wynne, O, Gartner, C, Borland, R, Baker, AL, Segan, CJ, Skelton, E, Moore, L, **Bathish, R**, Chiu, S, Guillaumier, A & **Lubman, DI**. (2021). **QuitNic: A Pilot Randomized Controlled Trial Comparing Nicotine Vaping Products With Nicotine Replacement Therapy for Smoking Cessation Following Residential Detoxification.** *Nicotine and Tobacco Research*, 23(3), 462-470.
17. Borg, K, Dumas, D, Andrew, E, **Smith, K**, Walker, T, Haworth, M & **Bragge, P**. (2020). **Ambulances are for emergencies: shifting behaviour through a research-informed behaviour change campaign.** *Health Research Policy and Systems*, 18(9).
18. Bui, T, Konstantatos, A, Liew, S, Christelis, ND & **Dooley, M**. (2020). **The impact of an innovative pharmacist-led inpatient opioid de-escalation intervention in post-operative orthopedic patients.** *Journal of opioid management*, 16(3), 167-176.
19. Burrows, T, **Verdejo-Garcia, A**, **Carter, A**, Brown, RM, Andrews, ZB, Dayas, CV, Hardman, CA, Loxton, N, Sumithran, P & Whatnall, M. (2020). **Health professionals' and health professional trainees' views on addictive eating behaviours: A cross-sectional survey.** *Nutrients*, 12(9), 2860.
20. Caluzzi, G, Livingston, M, Holmes, J, MacLean, S, **Lubman, D**, **Dietze, P**, Vashishtha, R, Herring, R & Pennay, A. (2021). **Declining drinking among adolescents: Are we seeing a denormalisation of drinking and a normalisation of non-drinking?** *Addiction*.
21. Campbell G, Noghrehchi F, **Nielsen S**, Clare P, Bruno R, Lintzeris N, Cohen M, Blyth F, Hall W, Larance B, Hungerford P, Dobbins T, Farrell M, and Degenhardt L. (2020). **Risk factors for indicators of opioid-related harms among people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study.** *EClinical Medicine*.
22. Campbell, TCH, **Reupert, AE**, Sutton, K, Basu, S, Davidson, G, Middeldorp, C, Naughton, M & Maybery, D. (2020). **Prevalence of mental illness among parents of children receiving treatment within child and adolescent mental health services (CAMHS): a scoping review.** *European Child and Adolescent Psychiatry*.
23. Cao, Z, Ottino-Gonzalez, J, Cupertino, RB, Schwab, N, Hoke, C, Catherine, O, Cousijn, J, Dagher, A, Foxe, JJ, Goudriaan, AE, Hester, R, Hutchison, K, Li, CSR, London, ED, Lorenzetti, V, Luijten, M, Martin-Santos, R, Momenan, R, Paulus, MP, Schmaal, L, Sinha, R, Sjoerds, Z, Solowij, N, Stein, DJ, Stein, EA, Uhlmann, A, van Holst, RJ, Veltman, DJ, Wiers, RW, **Yücel, M**, Zhang, S, Jahanshad, N, Thompson, PM, Conrod, P, Mackey, S & Garavan, H. (2021). **Mapping cortical and subcortical asymmetries in substance dependence: Findings from the ENIGMA Addiction Working Group.** *Addiction Biology*.
24. Castro-Calvo, J, King, DL, Stein, DJ, Brand, M, Carmi, L, Chamberlain, SR, Demetrovics, Z, Fineberg, NA, Rumpf, HJ, **Yücel, M**, Achab, S, Ambekar, A, Bahar, N, Blaszczynski, A, Bowden-Jones, H, Carbonell, X, Chan, EML, Ko, CH, de Timary, P, Dufour, M, Grall-Bronnec, M, Lee, HK, Higuchi, S, Jimenez-Murcia, S, Király, O, Kuss, DJ, Long, J, Müller, A, Pallanti, S, Potenza, MN, Rahimi-Movaghar, A, Saunders, JB, Schimmenti, A, Lee, SY, Siste, K, Spritzer, DT, Starcevic, V, Weinstein, AM, Wölfling, K & Billieux, J. (2021). **Expert appraisal of criteria for assessing gaming disorder: an international Delphi study.** *Addiction*.
25. Chien, WT, Bressington, D, **Lubman, DI** & Karatzias, T. (2020). **A randomised controlled trial of a caregiver-facilitated problem-solving based self-learning program for family carers of people with early psychosis.** *International Journal of Environmental Research and Public Health*, 17(24), 1-22.
26. Chitty, KM, **Schumann, J**, Chong, D, Hurzeler, TP, Buckley, N & Moran, L. (2020). **Reporting of alcohol as a contributor to death in Australian national suicide statistics and its relationship to post-mortem alcohol concentrations.** *Addiction*.
27. Chong, D, Buckley, N, **Schumann, J** & Chitty, KM. (2020). **Acute alcohol use in Australian coronial suicide cases, 2010–2015.** *Drug and Alcohol Dependence*, 212.
28. Choy, MA, **Sturgiss, E**, Goodyear-Smith, F & Smith, GJ. (2020). **Digital Health Tools and Patients With Drug Use Disorders: Qualitative Patient Experience Study of the Electronic Case-Finding and Help Assessment Tool (eCHAT).** *Journal of Medical Internet Research*, 22(9), e19256.
29. Christie, GIG, **Cheetham, A** & **Lubman, DI**. (2020). **Interventions for Alcohol and Drug Use Disorders in Young People: 10 Key Evidence-Based Approaches to Inform Service Delivery.** *Current Addiction Reports*, 7(4), 464-474.
30. Chu, M, Rago, MD, Mantinieks, D, Glowacki, L, Woodford, NW, **Gerostamoulos, D** & Drummer, OH. (2021). **Time-Dependent Changes in THC Concentrations in Deceased Persons.** *Journal of Analytical Toxicology*, 45(1), 1-7.
31. Chye, Y, Kirkham, R, Lorenzetti, V, McTavish, E, Solowij, N & **Yücel, M**. (2021). **Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence.** *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 6(6), 627-635.
32. Colledge, S, Larney, S, Bruno, R, Gibbs, D, Degenhardt, L, Yuen, WS, **Dietze, P** & Peacock, A. (2020). **Profile and correlates of injecting-related injuries and diseases among people who inject drugs in Australia.** *Drug and Alcohol Dependence*, 216, 108267.
33. Courtney, RJ, McRobbie, H, Tutka, P, Weaver, NA, **Petrie, D**, Mendelsohn, CP, Shakeshaft, A, Talukder, S, Macdonald, C, Thomas, D, Kwan, BCH, Walker, N, Gartner, C, Mattick, RP, Paul, C, Ferguson, SG, Zwar, NA, Richmond, RL, Doran, CM, Boland, VC, Hall, W, West, R & Farrell, M. (2021). **Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial.** *JAMA - Journal of the American Medical Association*, 326(1), 56-64.
34. Couto e Cruz, C, Salom, C, Parsell, C, **Dietze, P**, Burns, L & Alati, R. (2020). **Social domains of discrimination against people who inject drugs: Links with health and wellbeing.** *International Journal of Drug Policy*, 77, 102620.
35. Crossin, R & **Arunogiri, S**. (2020). **Harms associated with inhalant misuse in adolescent females – a review of the pre-clinical and clinical evidence.** *Drug and Alcohol Dependence*, 216, 108232.
36. Cullen, AJ, Dowling, NL, **Segrave, R**, Morrow, J, **Carter, A** & **Yücel, M**. (2021). **Considerations and practical protocols for using virtual reality in psychological research and practice, as evidenced through exposure-based therapy.** *Behavior Research Methods*, 53 (6), 2725–2742.
37. Curtis, A, Gooden, JR, Cox, CA, Harries, T, Peterson, V, Enticott, PG, Sanfilippo, PG, Miller, PG, **Lubman, DI** & **Manning, V**. (2021). **Neurocognitive functioning among people accessing an addiction neuropsychology clinic with and without a history of offending behaviour.** *Psychiatry, Psychology and Law*.
38. Davis, AC, Wright, CJC, Murphy, S, **Dietze, P**, Temple-Smith, MJ, Hellard, ME & Lim, MSC. (2020). **A digital pornography literacy resource co-designed with vulnerable young people: Development of "The Gist".** *Journal of Medical Internet Research*, 22 (6), e15964.
39. Dawson, JL, Sluggett, JK, **Schumann, JL**, Procter, NG & **Bell, JS**. (2021). **Fatal poisonings involving clozapine: A 16-year review of Australian coronial investigations.** *Australian and New Zealand Journal of Psychiatry*.
40. de Andrade, D, Coomber, K, Livingston, M, Taylor, N, Moayeri, F, Miller, PG, Ferris, J, Puljević, C, Mayshak, R & **Scott, D**. (2021). **The impact of late-night alcohol restrictions on ambulance call-outs in entertainment precincts.** *Drug and Alcohol Review*.
41. Debenham, J, Newton, N, Birrell, L, **Yücel, M**, Lees, B & Champion, K. (2020). **Cannabis and illicit drug use during neurodevelopment and the associated structural, functional and cognitive Outcomes: Protocol for a systematic review.** *JMIR Research Protocols*, 9(7), e18349.
42. Degenhardt L, Hungerford P, **Nielsen S**, Bruno R, Larance B, Clare P, Dobbins T, Hall W, Cohen M, Blyth F, Lintzeris N, Farrell M, and Campbell C. (2021). **Pharmaceutical opioid use patterns and indicators of extra-medical use and harm in adults with chronic non-cancer pain, 2012-2018: Findings from the Pain and Opioids IN Treatment (POINT) cohort.** *JAMA Network Open*.
43. Di Rico, R, **Nambiar, D**, Gabbe, B, **Stoové, M** & **Dietze, P**. (2020). **Patient-specific record linkage between emergency department and hospital admission data for a cohort of people who inject drugs: methodological considerations for frequent presenters.** *BMC Medical Research Methodology*, 20 (1), 283.
44. **Dietze, P**, Crossin, R, **Scott, D**, **Smith, K**, Wilson, J, Burgess, S, **Lubman, DI** & Cantwell, K. (2021). **Coding and classification of heroin overdose calls by MPDS dispatch software: Implications for bystander response with naloxone.** *Resuscitation*, 159, 13-18.
45. Douglass, CH, Raggatt, M, Wright, CJC, Reddan, H, O'Connell, H, Lim, MSC & **Dietze, PM**. (2021). **Alcohol consumption and illicit drug use among young music festival attendees in Australia.** *Drugs: Education, Prevention and Policy*.
46. Dowling, NA, Merkouris, SS, Rodda, SN, Smith, D, Aarsman, S, Lavis, T, **Lubman, DI**, Austin, DW, Cunningham, JA, Battersby, MW & Chul OS. (2021). **Gamblingless: A randomised trial comparing guided and unguided internet-based gambling interventions.** *Journal of Clinical Medicine*, 10 (11), 2224.
47. **Drummer, OH**, **Gerostamoulos, D**, LeBeau, MA & Pragst, F. (2021). **Concerns on the Misinterpretation of Very Low Drug Concentrations in Hair.** *Journal of Analytical Toxicology*, 44 (9), e6-e8.
48. Dumbili, E, **Gardner, J**, Degge, H & Hanewinkel, R. (2020). **Enhancement motivations for using prescription drugs among young adults in Nigeria.** *International Journal of Drug Policy*.
49. Emond, K, Bish, M, **Savic, M**, **Lubman, DI**, McCann, T, **Smith, K** & Mnatzaganian, G. (2021). **Characteristics of confidence and preparedness in paramedics in metropolitan, regional, and rural Australia to manage mental-health-related presentations: A cross-sectional study.** *International Journal of Environmental Research and Public Health*, 18 (4), 1882, 1-10.
50. Farrugia, A, Neale, J, Dwyer, R, Fomiatti, R, Fraser, S, Strang, J & **Dietze, P**. (2020). **Conflict and communication: managing the multiple affordances of take-home naloxone administration events in Australia.** *Addiction Research and Theory*, 28 (1), 29-37.

51. Faulkner, A, **Ogeil, RP**, Stojcevski, V & **Scott, D.** (2021). **Identifying points of prevention in firearm-related suicides: a mixed-methods study based on coronial records.** *Archives of Suicide Research.*

52. Fernando, H, Nehme, Z, Peter, K, Bernard, SA, Stephenson, M, Bray, J, Cameron, PA, Ellims, A, Taylor, A, Kaye, DM, **Smith, KL** & Stub, D. (2020). **Prehospital opioid dose and myocardial injury in patients with ST elevation myocardial infarction.** *Open Heart.*

53. Ferreira, GM, Lee, RSC, Piquet-Pessôa, M, de Menezes, GB, Moreira-de-Oliveira, ME, **Albertella, L**, **Yücel, M**, dos Santos Cruz, M, Dos Santos-Ribeiro, S & Fontenelle, LF. (2021). **Habitual versus affective motivations in obsessive-compulsive disorder and alcohol use disorder.** *CNS Spectrums*, 26 (3), 243-250.

54. Fetene D, Higgs P, **Nielsen S**, Djordjievic F, and **Dietze P.** (2020). **The impact of Victoria's real-time prescription monitoring system (Safescript) in a cohort of people who inject drugs.** *Medical Journal of Australia* 2020, 213(3), 141-141.

55. Fitzpatrick, RE, Robinson, AH, Rubenis, AJ, **Lubman, DI** & **Verdejo-Garcia, A.** (2021). **Lack of longitudinal changes in cognition in individuals with methamphetamine use disorder during the first 6 weeks after commencing treatment.** *American Journal of Drug and Alcohol Abuse.*

56. Foldi, CJ, **Liknaitzky, P**, **Williams, M** & Oldfield, BJ. (2020). **Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.** *Frontiers in Neuroscience*, 14, 43.

57. Fontenelle, LF, Oldenhof, E, Eduarda Moreira-de-Oliveira, M, Abramowitz, JS, Antony, MM, Cath, DC, **Carter, A**, Dougherty, D, Ferrão, YA, Figuee, M, Harrison, BJ, Hoexter, M, Soo Kwon, J, Küelz, A, Lazaro, L, Lochner, C, Marazziti, D, Mataix-Cols, D, McKay, D, Miguel, EC, Morein-Zamir, S, Moritz, S, Nestadt, G, O'Connor, KP, Pallanti, S, Purdon, C, Rauch, S, Richter, P, Rotge, JY, Shavitt, RG, Soriano-Mas, C, Starcevic, V, Stein, DJ, Steketee, G, Storch, EA, Taylor, S, van den Heuvel, OA, Veale, D, Woods, DW, Verdejo-Garcia, A, Yücel, M & The International OCDs Neuroscience Consensus Group. (2020). **A transdiagnostic perspective of constructs underlying obsessive-compulsive and related disorders: An international Delphi consensus study.** *Australian & New Zealand Journal of Psychiatry*, 54 (7), 719-731.

58. Foo, CT, O'Driscoll, DM, **Ogeil, RP**, **Lubman, D** & Young, AC. (2021). **Barriers to sleep in acute hospital settings.** *Sleep and Breathing.*

59. Francis, L & **Livingstone, C.** (2020). **Discourses of responsible gambling and gambling harm: observations from Victoria, Australia.** *Addiction Research and Theory.*

60. **Garfield, JBB** & **Lubman, DI.** (2021). **Associations between opioid dependence and sweet taste preference.** *Psychopharmacology*, 238, 1473-1484.

61. **Garfield, JBB**, Piercy, H, **Arunogiri, S**, **Lubman, DI**, Campbell, SC, **Sanfilippo, PG**, Gavin, J, Hopwood, M, Kotler, E, George, S, Okedara, G, Piccoli, LR & **Manning, V.** (2021). **Protocol for the methamphetamine approach-avoidance training (MAAT) trial, a randomised controlled trial of personalised approach bias modification for methamphetamine use disorder.** *Trials*, 22(1), 21.

62. Geddes, L, Iversen, J, Wand, H, Esmaeili, A, Tsui, J, Hellard, M, Dore, G, Grebely, J, **Dietze, P**, Bruneau, J, Prins, M, Morris, MD, Shoukry, NH, Lloyd, AR, Kim, AY, Lauer, G, Cox, AL, Page, K, Maher, L & for the International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3) Collaborative. (2020). **Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection.** *Clinical Infectious Diseases*, 70(1), 123-131.

63. Gibbs, D, Grebely, J, Sutherland, R, Larney, S, Butler, K, **Dietze, PM**, Starr, M & Peacock, A. (2021). **Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia.** *Drug and Alcohol Review.*

64. Gobarani, RK, Abramson, MJ, Bonevski, B, Weeks, GR, **Dooley, MJ**, Smith, BJ, Veale, A, Webb, A, Kirsas, S, Thomas, D, Miller, A, Gasser, R, Paul, E, Parkinson, J, Meanger, D, Coward, L, Kopsaftis, Z, Rofe, O, Lee, P & **George, J.** (2020). **The efficacy and safety of varenicline alone versus in combination with nicotine lozenges for smoking cessation among hospitalised smokers (VANISH): Study protocol for a randomised, placebo-controlled trial.** *BMJ Open*, 10(10), e038184.

65. Gobarani, RK, Zwar, NA, **Russell, G**, Abramson, MJ, Bonevski, B, Holland, AE, Paul, E, Cox, NS, Wilson, S & **George, J.** (2021). **Smoking cessation intervention in Australian general practice: a secondary analysis of a cluster randomised controlled trial.** *British Journal of General Practice*, 71(707), e458-e464.

66. Gooden, JR, Cox, CA, Petersen, V, Curtis, A, **Manning, V** & **Lubman, DI.** (2021). **Characterisation of presentations to a community-based specialist addiction neuropsychology service: Cognitive profiles, diagnoses and comorbidities.** *Drug and Alcohol Review*, 40(1), 83-92.

67. Goutzamanis, S, Spelman, T, Harney, B, **Dietze, P**, **Stoove, M**, Higgs, P, Thompson, A, **Doyle, JS** & Hellard, M. (2021). **Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.** *Journal of Viral Hepatitis*, 28(7), 1068-1077.

68. Grace, S, Rossetti, MG, Allen, N, Batalla, A, Bellani, M, Brambilla, P, Chye, Y, Cousijn, J, Goudriaan, AE, Hester, R, Hutchison, K, Labuschagne, I, Momenan, R, Martin-Santos, R, Rendell, P, Solowij, N, Sinha, R, Li, CSR, Schmaal, L, Sjoerds, Z, Suo, C, Terrett, G, van Holst, RJ, Veltman, DJ, **Yücel, M**, Thompson, P, Conrod, P, Mackey, S, Garavan, H & Lorenzetti, V. (2021). **Sex differences in the neuroanatomy of alcohol dependence: hippocampus and amygdala subregions in a sample of 966 people from the ENIGMA Addiction Working Group.** *Translational Psychiatry*, 11(1), 156.

69. Gurvich, CT, Thomas, N, Hudaib, A-R, Sood, L, Fabiato, K, Sutton, K, Isaacs, A, **Arunogiri, S**, Sharp, G & Kulkarni, J. (2021). **Coping styles and mental health in response to societal changes during the COVID-19 pandemic.** *International Journal of Social Psychiatry*, 67 (5), 540-549.

70. Hahn, S, Mackey, S, Cousijn, J, Foxe, JJ, Heinz, A, Hester, R, Hutchinson, K, Kiefer, F, Korucuoglu, O, Lett, T, Li, CSR, London, E, Lorenzetti, V, Maartje, L, Momenan, R, Orr, C, Paulus, M, Schmaal, L, Sinha, R, Sjoerds, Z, Stein, DJ, Stein, E, van Holst, RJ, Veltman, D, Walter, H, Wiers, RW, **Yücel, M**, Thompson, PM, Conrod, P, Allgaier, N & Garavan, H. (2020). **Predicting alcohol dependence from multi-site brain structural measures.** *Human Brain Mapping.*

71. **Haines S**, **Savic M**, **Picco L**, **Nielsen S**, and **Carter A.** (2020). **Unintended consequences of Real-Time Prescription Monitoring: Ensure the ethical implementation to minimise harm.** *Medical Journal of Australia*, 213(3), 142-142.

72. Hanegraaf, L, van Baal, S, Hohwy, J & **Verdejo-Garcia, A.** (2021). **A systematic review and meta-analysis of 'Systems for Social Processes' in borderline personality and substance use disorders.** *Neuroscience and Biobehavioral Reviews*, 127, 572-592.

73. Herrenkohl, TI, **Scott, D**, Higgins, DJ, Klika, JB & Lonne, B. (2021). **How COVID-19 Is Placing Vulnerable Children at Risk and Why We Need a Different Approach to Child Welfare.** *Child Maltreatment*, 26 (1), 9-16.

74. Ho, D & **Verdejo-Garcia, A.** (2021). **Interactive influences of food, contexts and neurocognitive systems on addictive eating.** *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 110, 110295.

75. Hopkins, RE, Bui, T, Konstantatos, AH, Arnold, C, Magliano, DJ, Liew, D & **Dooley, MJ.** (2020). **Educating junior doctors and pharmacists to reduce discharge prescribing of opioids for surgical patients: a cluster randomised controlled trial.** *Medical Journal of Australia*, 213(9), 417-423.

76. Hurzeler, T, Buckley, NA, Noghrehchi, F, Malouf, P, Page, A, **Schumann, JL** & Chitty, KM. (2021). **Alcohol-related suicide across Australia: a geospatial analysis.** *Australian and New Zealand Journal of Public Health.*

77. Ince, C, **Yücel, M**, **Albertella, L** & Fontenelle, LF. (2020). **Exploring the clinical profile of problematic pornography use.** *CNS Spectrums.*

78. Jones N, Hickman M, Larney L, **Nielsen S**, Ali R, Murphy T, Dobbins T, Fiellin D, and Degenhardt L. (2021). **Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001-2018: findings from the OATS retrospective cohort study.** *Drug and Alcohol Dependence*, 218:108354.

79. Jones N, **Nielsen S**, Farrell, M, Ali, R, Gill A, Larney S, and Degenhardt L. (2021) **Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.** *Drug and Alcohol Dependence*, 219:108464.

80. Jin, X, Kinner, SA, Hopkins, R, Stockings, E, Courtney, RJ, Shakeshaft, A, **Petrie, D**, Dobbins, T, Puljevic, C, Chang, S & Dolan, K. (2020). **A randomised controlled trial of motivational interview for relapse prevention after release from smoke-free prisons in Australia.** *International Journal of Prisoner Health.*

81. Kelly, PJ, Beck, AK, Baker, AL, Deane, FP, Hides, L, **Manning, V**, Shakeshaft, A, Larance, B, Neale, J, Kelly, J, Oldmeadow, C, Searles, A, Treloar, C, Gray, RM, Argent, A & McGlaughlin, R. (2020). **Feasibility of a mobile health app for routine outcome monitoring and feedback in mutual support groups coordinated by SMART recovery Australia: Protocol for a pilot study.** *JMIR Research Protocols*, 9 (7), e15113.

82. Kelly, PJ, Beck, AK, Deane, FP, Larance, B, Baker, AL, Hides, L, **Manning, V**, Shakeshaft, A, Neale, J, Kelly, JF, Oldmeadow, C, Searles, A, Palazzi, K, Lawson, K, Treloar, C, Gray, RM, Argent, A & McGlaughlin, R. (2021). **Feasibility of a mobile health app for routine outcome monitoring and feedback in SMART recovery mutual support groups: Stage 1 mixed methods pilot study.** *Journal of Medical Internet Research*, 23 (10), e25217.

83. **Lam, T**, Fischer, J, Salom, C, **Ogeil, R**, **Wilson, J**, **Lubman, DI**, Burns, L, Lenton, S, Gilmore, W, Chikritzhs, T, Aiken, A & Allsop, S. (2020). **Safety first: Beliefs of older peers supplying alcohol to underage friends.** *Health Promotion Journal of Australia.*

84. **Lam, T**, **Hayman, J**, **Berecki-Gisolf, J**, **Sanfilippo, P**, **Lubman, DI** & **Nielsen, S.** (2020). **Comparing rates and characteristics of emergency department presentations related to pharmaceutical opioid poisoning in Australia: a study protocol for a retrospective observational study.** *BMJ Open*, 10(9), 038979.

85. Larance B, Byrne M, Lintzeris N, **Nielsen S**, Grebely J, Degenhardt D, Shahbazi J, Shanahan M, Lancaster K, Dore G, Ali R, and Farrell M. (2020). **An open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study.** *BMJ Open* 2020, 10:e034398

86. Larney S, Jones N, Fiellin DA, **Nielsen S**, Hickman M, Dobbins T, Murphy T, Ali R, and Degenhardt L. (2020). **Data resource profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia.** *International Journal of Epidemiology*, 49(6), 1774-1775.

87. Leary, M, Pursey, KM, **Verdejo-Garcia, A** & Burrows, TL. (2021). **Current intervention treatments for food addiction: A systematic review.** *Behavioral Sciences*, 11 (6), 80.

88. Lintzeris, N, Dunlop, AJ, Haber, PS, **Lubman, DI**, Graham, R, Hutchinson, S, **Arunogiri, S**, Hayes, V, Hjelmström, P, Svedberg, A, Peterson, S & Tibergh, F. (2021). **Patient-Reported Outcomes of Treatment of Opioid Dependence with Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.** *JAMA Network Open*, 4(5), e219041.

89. Lewer D, Jones N, Hickman M, Ezard N, **Nielsen S**, and Degenhardt L. (2020). **Risk of discharge against medical advice among hospital in patients with a history of opioid agonist therapy in New South Wales, Australia: a cohort study and nested crossover-cohort analysis.** *Drug and Alcohol Dependence*, 217:108343.

90. Lewer D, Jones N, Hickman M, **Nielsen S**, and Degenhardt L. (2020). **Life expectancy of people who are dependent on opioids: a cohort study in New South Wales, Australia.** *Journal of Psychiatric Research*, 130, 435-440

91. Liu, C, Rotaru, K, Lee, R, Tiego, J, Suo, C, **Yücel, M** & **Albertella, L.** (2021). **Distress-driven impulsivity interacts with cognitive inflexibility to determine addiction-like eating.** *Journal of Behavioral Addictions.*

92. Liu, C, **Yücel, M**, Suo, C, Le Pelley, ME, Tiego, J, Rotaru, K, Fontenelle, LF & **Albertella, L.** (2021). **Reward-related attentional capture moderates the association between fear-driven motives and heavy drinking.** *European Addiction Research.*

93. **Lubman, DI**, Heilbronn, C, **Ogeil, RP**, Killian, JJ, Matthews, S, **Smith, K**, Bosley, E, Carney, R, McLaughlin, K, Wilson, A, Eastham, M, Shipp, C, Witt, K, Lloyd, B & **Scott, D.** (2020). **National Ambulance Surveillance System: A novel method using coded Australian ambulance clinical records to monitor self-harm and mental health-related morbidity.** *PLoS ONE*, 15 (7 July), e0236344.

94. Man, N, Chranowska, A, Price, O, Bruno, R, **Dietze, PM**, Sisson, SA, Degenhardt, L, Salom, C, Morris, L, Farrell, M & Peacock, A. (2021). **Trends in cocaine use, markets and harms in Australia, 2003–2019.** *Drug and Alcohol Review*, 40 (6), 946-956.

95. MacLean, S, Dwyer, R, Pennay, A, **Savic, M**, Wilkinson, C, **Roberts, S**, Turner, K, Saleeba, E & Room, R. (2020). **The 'social worlds' concept: a useful tool for public health-oriented studies of drinking cultures.** *Addiction Research & Theory.*

96. Maltman, K, **Savic, M**, **Manning, V**, Dilkes-Frayne, E, **Carter, A** & **Lubman, DI.** (2020). **'Holding on' and 'letting go': a thematic analysis of Australian parent's styles of coping with their adult child's methamphetamine use.** *Addiction Research & Theory*, 28(4), 345-353.

97. **Manning, V**, Dowling, NA, Rodda, SN, **Cheetham, A** & **Lubman, DI.** (2020). **An Examination of Clinician Responses to Problem Gambling in Community Mental Health Services.** *Journal of Clinical Medicine*, 9(7), 2075.

98. **Manning, V**, **Garfield, JBB**, Staiger, PK, **Lubman, DI**, Lum, JAG, Reynolds, J, Hall, K, Bonomo, Y, Lloyd-Jones, M, Wiers, RW, Piercy, H, Jacka, D & **Verdejo-Garcia, A.** (2021). **Effect of Cognitive Bias Modification on Early Relapse among Adults Undergoing Inpatient Alcohol Withdrawal Treatment: A Randomized Clinical Trial.** *JAMA Psychiatry*, 78(2), 133-140.

99. **Manning, V**, Piercy, H, **Garfield, JBB** & **Lubman, DI.** (2020). **Personalized approach bias modification smartphone app ("SWIPE") to reduce alcohol use among people drinking at hazardous or harmful levels: Protocol for an open-label feasibility study.** *JMIR Research Protocols*, 9(8), e21278.

100. Mantinielis, D, **Gerostamoulos, D**, Glowacki, L, Di Rago, M, **Schumann, J**, Woodford, NW & **Drummer, OH.** (2021). **Postmortem Drug Redistribution: A Compilation of Postmortem/Antemortem Drug Concentration Ratios.** *Journal of Analytical Toxicology*, 45(4), 368-377.

101. Mathieson, S, Wertheimer, G, Maher, CG, Christine Lin, CW, McLachlan, AJ, **Buchbinder, R**, Pearson, SA & Underwood, M. (2020). **What proportion of patients with chronic noncancer pain are prescribed an opioid medicine? Systematic review and meta-regression of observational studies.** *Journal of Internal Medicine*, 287(5), 458-474.

102. Mayshak, R, Curtis, A, Coomber, K, Tonner, L, Walker, A, Hyder, S, **Liknaitzky, P** & Miller, P. (2020). **Alcohol-Involved Family and Domestic Violence Reported to Police in Australia.** *Journal of Interpersonal Violence*.

103. McCann, TV, Stephenson, J & **Lubman, DI**. (2020). **Family Stress, Well-Being and Hope for the Future When Supporting a Relative with AOD Misuse: A Cross-Sectional Survey.** *Issues in Mental Health Nursing*.

104. McDonald, H, **Berecki-Gisolf, J**, **Stephan, K** & Newstead, S. (2020). **Preventing road crashes: do infringements for traffic offences have a deterrent effect amongst drivers aged 40+? An examination of administrative data from Victoria, Australia.** *Transportation Research Part F: Traffic Psychology and Behaviour*, 69, 91-100.

105. McKetin, R, Dean, OM, Turner, A, Kelly, PJ, Quinn, B, **Lubman, DI**, **Dietze, P**, Carter, G, Higgs, P, Sinclair, B, Reid, D, Baker, AL, Manning, V, Pas, NT, Thomas, T, Bathish, R, Raftery, DK, Wrobel, A, Saunders, L, **Arunogiri, S**, Cordaro, F, Hill, H, Hall, S, Clare, PJ, Mohebbi, M & Berk, M. (2021). **N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial.** *EclinicalMedicine*, 38, 101005.

106. McKetin, R, Quinn, B, Higgs, P, Berk, M, Dean, OM, Turner, A, Kelly, PJ, **Lubman, DI**, Carter, G, Baker, AL, **Manning, V**, Thomas, T, **Bathish, R**, Raftery, D, Saunders, L, Wrobel, A, Meehan, A, Sinclair, B, Reid, D, **Arunogiri, S**, Hill, H, Cordaro, F & **Dietze, PM**. (2020). **Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial.** *Drug and Alcohol Review*.

107. Meikle, SE, **Liknaitzky, P**, Rossell, SL, Ross, M, Strauss, N, Thomas, N, Murray, G, **Williams, M** & Castle, DJ. (2020). **Psilocybin-assisted therapy for depression: How do we advance the field?.** *Australian and New Zealand Journal of Psychiatry*, 54(3), 225-231.

108. **Mendes, P**. (2021). **Conditionalising the unemployed: Why have consecutive Australian governments refused to increase the inadequate Newstart Allowance?** *Australian Journal of Social Issues*, 56 (1), 42-53.

109. **Mendes, P** & Philp, JP. (2021). **Relationship-based models for supporting young people transitioning from out-of-home care: Two case studies from Victoria, Australia.** *Institutionalised Children Explorations and Beyond*, 8 (1), 120–132.

110. **Mendes, P**, Roche, S, Marston, G, Peterie, M, Staines, Z & Humpage, L. (2020). **The Social Harms Outweigh the Benefits: A Study of Compulsory Income Management in Greater Shepparton and Playford.** *Australian Social Work*.

111. **Mendes, P**, Roche, S, Marston, G, Bielefeld, S, Peterie, M, Staines, Z & Humpage, L. (2021). **Is conditional welfare an effective means for reducing alcohol and drug abuse? An exploration of compulsory income management across four Australian trial sites.** *Australian Journal of Political Science*.

112. Moradmand-Badie, B, Tran L, Oikarainen N, Degenhardt L, **Nielsen S**, Roberts J, Ward S, Bowman J, and Larney S. (2020). **Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, Australia.** *Drug and Alcohol Review*, 40(1), 98-108.

113. Morphett, K, Puljević, C, Borland, R, **Carter, A**, Hall, W & Gartner, C. (2021). **Attitudes towards a hypothetical 'clean nicotine' product and harm reduction among smokers.** *International Journal of Drug Policy*, 88, 103020.

114. **Nambiar, D**, Pearce, JW, Bray, J, Stephenson, M, Nehme, Z, Masters, S, Brink, D, **Smith, K**, Arendts, G, Fatovich, D, Bernard, S, Haskins, B, Grantham, H & Cameron, P. (2020). **Variations in the care of agitated patients in Australia and New Zealand ambulance services.** *Emergency Medicine Australasia*, 32(3), 438–445.

115. Navarri, X, Afzali, MH, Sinha, R, Stein, DJ, Momenan, R, Veltman, DJ, Korucuoglu, O, Sjoerds, Z, van Holst, RJ, Hester, R, Orr, C, Cousijn, J, **Yucei, M**, Lorenzetti, V, Wiers, R, Jahanshad, N, Glahn, DC, Thompson, PM, Mackey, S & Conrod, PJ. (2020). **How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross-disorder meta-analytic comparison using the ENIGMA consortium findings.** *Human Brain Mapping*.

116. Neale, J, Farrugia, A, Campbell, AN, **Dietze, P**, Dwyer, R, Fomiatti, R, Jones, JD, Comer, SD, Fraser, S & Strang, J. (2021). **Understanding preferences for type of take-home naloxone device: international qualitative analysis of the views of people who use opioids.** *Drugs: Education, Prevention and Policy*.

117. **Nielsen S**, Gisev N, Leung J, Clare P, Bruno R, Lintzeris N, Larence B, Blyth F, Hall W, Cohen M, Degenhardt L, Farrell M, and Campbell G. (2021). **Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study.** *British Journal of Clinical Pharmacology*, 87(6), 3092-3104.

118. **Nielsen S** and Olsen A. (2021). **Using the Behaviour Change Wheel to understand and address barriers to pharmacy naloxone supply in Australia.** *International Journal of Drug Policy*, 90:103061.

119. **Nielsen, S**, **Sanfilippo, P**, Belackova, V, Day, C, Silins, E, Lintzeris, N, Bruno, R, Grebely, J, Lancaster, K, Ali, R, Bell, J, **Dietze, P**, Degenhardt, L, Farrell, M & Larence, B. (2021). **Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities.** *Addiction*, 116 (6), 1482-1494.

120. **Nielsen S**, **Sanfilippo P**, **Picco L**, Bruno R, Kowalski M, Wood P, and Larney S. (2020). **What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy.** *International Journal of Clinical Pharmacy*, 43(2), 420-429.

121. **Nielsen, S**, **Sanfilippo, PG**, **Scott, D**, **Lam, T**, **Smith, K** & **Lubman, DI**. (2021). **Characteristics of oxycodone-related ambulance attendances: analysis of temporal trends and the effect of reformulation in Victoria, Australia from 2013 to 2018.** *Addiction*.

122. O'Brien, H, Callinan, S, **Livingston, M**, **Doyle, JS** & **Dietze, PM**. (2020). **Population patterns in Alcohol Use Disorders Identification Test (AUDIT) scores in the Australian population; 2007–2016.** *Australian and New Zealand Journal of Public Health*.

123. O'Brien, H, Di Rico, R, Dean, E, Smoker, G, Lloyd-Jones, M, McKechnie, M, **Dietze, PM** & **Doyle, JS**. (2021). **Screening for risky drinkers among hospitalised inpatients using the AUDIT: A feasibility, point prevalence and data linkage study.** *Drug and Alcohol Review*, 41, 293-302.

124. O'Donnell, R, Hatzikiakidis, K, **Mendes, P**, Savaglio, M, Green (nee Cox), R, Kerridge, G, Currie, G & Skouteris, H. (2020). **The impact of transition interventions for young people leaving care: a review of the Australian evidence.** *International Journal of Adolescence and Youth*, 25 (1), 1076-1088.

125. O'Donnell, R, Macrae, A, Savaglio, M, Vicary, D, Green (nee Cox), R, **Mendes, P**, Kerridge, G, Currie, G, Diamond, S & Skouteris, H. (2020). **"It was daunting. I was 18 and I left residential care and there was no support whatsoever": A scoping study into the transition from out-of-home-care process in Tasmania, Australia.** *Children Australia*, 45 (4), 296-304.

126. **Ogeil, RP**, Prasad, S, O'Driscoll, DM, Li, WYH, **Lubman, DI** & Young, AC. (2020). **Psychoactive drug and medication use among patients referred to a tertiary sleep laboratory population.** *Psychiatry Research*, 294, 113545.

127. **Ogeil, RP**, **Savic, M**, Ferguson, N & **Lubman, DI**. (2021). **Shift-work-play: Understanding the positive and negative experiences of male and female shift workers to inform opportunities for intervention to improve health and wellbeing.** *Australian Journal of Advanced Nursing*, 38 (2), 23-33.

128. **Ogeil, RP**, **Scott, D**, Faulkner, A, **Wilson, J**, Beard, N, **Smith, K**, **Manning, V** & **Lubman, DI**. (2021). **Changes in alcohol intoxication-related ambulance attendances during COVID-19: How have government announcements and policies affected ambulance call outs?.** *The Lancet Regional Health - Western Pacific*, 14, 100222.

129. O'Keefe, D, Ritter, A, **Stoove, M**, Hughes, C & **Dietze, P**. (2020). **Harm reduction programs and policy in Australia: barriers and enablers to effective implementation.** *Sucht*, 66(1), 33-43.

130. Palmer, A, Higgs, P, Scott, N, Agius, P, Maher, L & **Dietze, P**. (2020). **Prevalence and correlates of simultaneous, multiple substance injection (co-injection) among people who inject drugs in Melbourne, Australia.** *Addiction*, 116(4), 876-888.

131. Palmer, A, Scott, N, **Dietze, P** & Higgs, P. (2020). **Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: A qualitative study.** *Harm Reduction Journal*, 17(1), 14.

132. Palmer, AY, Wilkinson, A, Aitken, C, **Dietze, P**, Dore, GJ, Maher, L, Sacks-Davis, R, **Stoove, M**, Wilson, D, Hellard, M & Scott, N. (2021). **Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment.** *Journal of Gastroenterology and Hepatology*, 36 (8), 2270-2274.

133. Payne, JE, Chambers, R & **Liknaitzky, P**. (2021). **Combining psychedelic and mindfulness interventions: Synergies to inform clinical practice.** *ACS Pharmacology and Translational Science*, 4(2), 416-423.

134. Pérez de los Cobos, J, Alcaraz, S, **Verdejo-García, A**, Muñoz, L, Siñol, N, Fernández-Serrano, MJ, Fernández, P, Martínez, A, Duran-Sindreu, S, Battle, F & Trujols, J. (2021). **Factors associated with the absence of cocaine craving in treatment-seeking individuals during inpatient cocaine detoxification.** *American Journal of Drug and Alcohol Abuse*, 47(1), 127-138.

135. Perkins, D, Sarris, J, Rossell, S, Bonomo, Y, Forbes, D, Davey, C, Hoyer, D, Loo, C, Murray, G, Hood, S, Schubert, V, Galvão-Coelho, NL, O'Donnell, M, Carter, O, **Liknaitzky, P**, **Williams, M**, Siskind, D, Penington, D, Berk, M & Castle, D. (2021). **Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.** *Australian and New Zealand Journal of Psychiatry*, , 55(2).

136. Peterie, M, Marston, G, Humpage, L, **Mendes, P**, Bielefeld, S & Staines, Z. (2021). **The trope of the vulnerable child in conditional welfare discourses: An Australian case study.** *Journal of Sociology*

137. Phillips, JG, Currie, J, **Ogeil, RP** & Vaeau, F. (2020). **Drug and alcohol counsellors' opinions of therapist negotiated location aware outpatient support using a mobile app.** *British Journal of Guidance and Counselling*, 48(2), 240-250.

138. **Picco L**, **Middleton M**, Bruno R, Kowalski M, & **Nielsen S**. (2020). **Validity and reliability of the online Routine Opioid Outcome Monitoring (ROOM) tool.** *Pain Medicine*, 21(12), 3645-3654.

139. **Picco L**, **Middleton M**, Bruno R, Kowalski M, & **Nielsen S**. (2020). **Validation of the OWLS, a screening tool for measuring prescription opioid use disorder in primary care.** *Pain Medicine*, 21 (11), 2757–2764.

140. Piercy, H, **Garfield, JBB**, **Lubman, DI**, **Lam, T** & **Manning, V**. (2021). **Improved rates of treatment success following alcohol and other drug treatment among clients who quit or reduce their tobacco smoking.** *Drug and Alcohol Review*, 40(1), 78-82.

141. Piercy, H, **Manning, V** & Staiger, PK. (2021). **Pushing or Pulling Your "Poison": Clinical Correlates of Alcohol Approach and Avoidance Bias Among Inpatients Undergoing Alcohol Withdrawal Treatment.** *Frontiers in Psychology*, 12, 663087.

142. **Prathivadi, P** & **Sturgiss, EA**. (2021). **When will opioid agonist therapy become a normal part of comprehensive health care?.** *Medical Journal of Australia*, 214(11), 504-505.e1

143. **Prathivadi, P**, **Barton, C** & Mazza, D. (2020). **Qualitative insights into the opioid prescribing practices of Australian GP.** *Family Practice*, 37(3), 412-417.

144. **Prathivadi, P**, Lockett, T, **Barton, C**, Holliday, S & Mazza, D. (2021). **General practitioner attitudes towards systems-level opioid prescribing interventions: A pooled secondary qualitative analysis.** *Australian Journal of General Practice*, 50(5), 309-316.

145. Price, O, Man, N, Bruno, R, **Dietze, P**, Salom, C, Lenton, S, **Grigg, J**, Gibbs, D, Wilson, T, Degenhardt, L, Chan, R, Thomas, N & Peacock, A. (2021). **Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016–20.** *Addiction*.

146. Prior, K, Saleminck, E, Wiers, RW, Teachman, BA, Piggott, M, Newton, NC, Teesson, M, Baillie, AJ, **Manning, V**, McLellan, LF, Mahoney, A & Stapinski, LA. (2021). **A web-based cognitive bias modification intervention (Re-train Your Brain) for emerging adults with co-occurring social anxiety and hazardous alcohol use: Protocol for a multiarm randomized controlled pilot trial.** *JMIR Research Protocols*, 10(7), e28667.

147. Quinn, B, Pearson, R, Cutts, J, Seed, C, Scott, N, Hoad, V, **Dietze, P**, Wilson, D, Maher, L, Thompson, A, Farrell, M, Harrod, M, Caris, S, Pink, J, Kotsiou, G & Hellard, M. (2020). **Blood donation amongst people who inject drugs in Australia: research supporting policy change.** *Vox Sanguinis*, 115(3), 162-170.

148. Quinn, B, Ward, B, Agius, P, Jenkinson, R, Hickman, M, Sutton, K, Hall, C, McKetin, R, Farrell, MP, Cossar, R & **Dietze, PM**. (2020). **A prospective cohort of people who use methamphetamine in Melbourne and non-metropolitan Victoria, Australia: Baseline characteristics and correlates of methamphetamine dependence.** *Drug and Alcohol Review*, 40(7), 1239-1248.

149. Radfar, SR, De Jong, CAJ, Farhoudian, A, Ebrahimi, M, Rafei, P, Vahidi, M, Yunesian, M, Kouimtsidis, C, **Arunogiri, S**, Massah, O, Deylamizadeh, A, Brady, KT, Busse, A, Potenza, MN, Ekhtiari, H, Baldacchino, AM & ISAM-PPIG Global Survey Consortium. (2021). **Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey.** *Frontiers in Psychiatry*, 12, 639393.

150. Raftery, D, Kelly, PJ, Deane, FP, Baker, AL, Ingram, I, Goh, MCW, **Lubman, DI**, Carter, G, Turner, A, Dean, OM, Sinclair, BL & Mcketin, R. (2020). **Insight in substance use disorder: A systematic review of the literature.** *Addictive Behaviors*, 111, 106549.

151. Rakesh, D, Lv, J, Zalesky, A, Allen, NB, **Lubman, DI, Yücel, M** & Whittle, S. (2021). **Altered resting functional connectivity patterns associated with problematic substance use and substance use disorders during adolescence.** *Journal of Affective Disorders*, 279, 599-608.

152. Ringin, E, Cropley, V, Zalesky, A, Bruggemann, J, **Sundram, S**, Weickert, CS, Weickert, TW, Bousman, CA, Pantelis, C & Van Rheenen, TE. (2021). **The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disorders.** *Psychological Medicine.*, 1-19.

153. Roberts, CA, Lorenzetti, V, Albein-Urios, N, Kowalczyk, MA, Martinez-Gonzalez, JM & **Verdejo-Garcia, A.** (2021). **Do comorbid personality disorders in cocaine dependence exacerbate neuroanatomical alterations? A structural neuroimaging study.** *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 110, 110298.

154. Robinson, AH, Perales, JC, **Volpe, I**, Chong, TTJ & **Verdejo-Garcia, A.** (2021). **Are methamphetamine users compulsive? Faulty reinforcement learning, not inflexibility, underlies decision making in people with methamphetamine use disorder.** *Addiction Biology*, 26(4), e12999.

155. Roche, S, **Mendes, P**, Marston, G, Bielefeld, S, Peterie, M, Staines, Z & Humpage, L. (2021). **Examining the Consequences of Welfare Conditionality: A Case Study of Compulsory Income Management in the Regional Community of Ceduna, Australia.** *Social Policy and Society*, 1-16.

156. Romei, A, **Voigt, K** & **Verdejo-Garcia, A.** (2020). **A perspective on candidate neural underpinnings of Binge Eating Disorder: Reward and homeostatic systems.** *Current Pharmaceutical Design*, 26(20), 2327-2333.

157. Romero-Garcia, R, Hook, RW, Tiego, J, Bethlehem, RAI, Goodyer, IM, Jones, PB, Dolan, R, Grant, JE, Bullmore, ET, **Yücel, M** & Chamberlain, SR. (2021). **Brain micro-architecture and disinhibition: a latent phenotyping study across 33 impulsive and compulsive behaviours.** *Neuropsychopharmacology*, 46 (2), 423-431.

158. Rossetti, MG, Mackey, S, Patalay, P, Allen, NB, Batalla, A, Bellani, M, Chye, Y, Conrod, P, Cousijn, J, Garavan, H, Goudriaan, AE, Hester, R, Martin-Santos, R, Solowij, N, Suo, C, Thompson, PM, **Yücel, M**, Brambilla, P & Lorenzetti, V. (2021). **Sex and dependence related neuroanatomical differences in regular cannabis users: findings from the ENIGMA Addiction Working Group.** *Translational Psychiatry*, 11(1), 272.

159. Rossetti, MG, Patalay, P, Mackey, S, Allen, NB, Batalla, A, Bellani, M, Chye, Y, Cousijn, J, Goudriaan, AE, Hester, R, Hutchison, K, Li, CSR, Martin-Santos, R, Momenan, R, Sinha, R, Schmaal, L, Sjoerds, Z, Solowij, N, Suo, C, van Holst, RJ, Veltman, DJ, **Yücel, M**, Thompson, PM, Conrod, P, Garavan, H, Brambilla, P & Lorenzetti, V. (2021). **Gender-related neuroanatomical differences in alcohol dependence: findings from the ENIGMA Addiction Working Group.** *NeuroImage: Clinical*, 30, 102636.

160. **Roxburgh, A**, Jauncey, M, Day, C, Bartlett, M, Cogger, S, **Dietze, P, Nielsen, S**, Latimer, J & Clark, N. (2021). **Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia.** *Harm Reduction Journal*, 18 (1), 20.

161. Sahle, BW, Reavley, NJ, Li, W, Morgan, AJ, **Yap, MBH, Reupert, A** & Jorm, AF. (2021). **The association between adverse childhood experiences and common mental disorders and suicidality: an umbrella review of systematic reviews and meta-analyses.** *European Child and Adolescent Psychiatry*.

162. Salter, H, Hutton, J, Cantwell, K, Dietze, P, Higgs, P, Straub, A, Zordan, R & Lloyd-Jones, M. (2020). **Review article: Rapid review of the emergency department-initiated buprenorphine for opioid use disorder.** *EMA-Emergency medicine Australasian*, 36(6), 924-934.

163. Schumann, J, Perkins, M, **Dietze, P**, Nambiar, D, Mitra, B, Gerostamoulos, D, Drummer, OH, Cameron, P, Smith, K & Beck, B. (2021). **The prevalence of alcohol and other drugs in fatal road crashes in Victoria, Australia.** *Accident Analysis and Prevention*, 153, 105905.

164. **Scott, D, Ogeil, RP**, Maoyeri, F, Heilbronn, C, Coomber, K, **Smith, K**, Miller, PG & **Lubman, DI.** (2021). **Alcohol Accessibility and Family Violence-related Ambulance Attendances.** *Journal of Interpersonal Violence*.

165. Staiger, PK & **Liknaitzky, P.** (2020). **An alternative goal-setting technique for addictive behaviour interventions: The Chronos Approach.** *Clinical Psychologist*, 25(2), 124-130.

166. Staiger, PK, **Liknaitzky, P**, Lake, AJ & Gruenert, S. (2020). **Longitudinal Substance Use and Biopsychosocial Outcomes Following Therapeutic Community Treatment for Substance Dependence.** *Journal of Clinical Medicine*, 9(1), 118.

167. Staiger, PK, O'Donnell, R, **Liknaitzky, P**, Bush, R & Milward, J. (2020). **Mobile Apps to Reduce Tobacco, Alcohol, and Illicit Drug Use: Systematic Review of the First Decade.** *Journal of Medical Internet Research*, 22(11), e17156.

168. Staines, Z, Marston, G, Bielefeld, S, Humpage, L, **Mendes, P** & Peterie, M. (2021). **Governing Poverty: Compulsory Income Management and Crime in Australia.** *Critical Criminology*, 29 (4), 745-761.

169. Stavropoulos, V, Baynes, KL, O'Farrell, D, Gomez, R, Mueller, A, **Yucel, M** & Griffiths, M. (2020). **Inattention and Disordered Gaming: Does Culture Matter?.** *Psychiatric Quarterly*, 91(2), 333-348.

170. Stavropoulos, V, Gomez, R, Mueller, A, **Yucel, M** & Griffiths, M. (2020). **User-avatar bond profiles: How do they associate with disordered gaming?.** *Addictive Behaviors*, 103, 106245.

171. Stewart, AC, Peacock, A, Djordjevic, F, Cossar, R, Salom, C, Lenton, S & **Dietze, P.** (2021). **Ketamine use among people who regularly use ecstasy and other illicit stimulants in Australia: Trends and characteristics of use, 2009–2019.** *Journal of Studies on Alcohol and Drugs*, 82 (2), 188-196.

172. Sulkunen, P, Babor, TF, Cisneros Örnberg, J, Egerer, M, Hellman, M, **Livingstone, C**, Marionneau, V, Nikkinen, J, Orford, J, Room, R & Rossow, I. (2020). **Setting Limits: Gambling, Science and Public Policy—summary of results.** *Addiction*, 116(1), 32-40.

173. Sutherland, R, **Dietze, PM**, Gisev, N, Bruno, R, Campbell, G, Memedovic, S & Peacock, A. (2020). **Patterns and correlates of prescribed and non-prescribed pregabalin use among a sample of people who inject drugs in Australia.** *Drug and Alcohol Review*, 39(5), 568-574.

174. Sutherland, R, Jayathilake, R, Peacock, A, **Dietze, P**, Bruno, R, Reddel, S & Gisev, N. (2021). **Trends and characteristics of extra-medical use of quetiapine among people who regularly inject drugs in Australia, 2011–2018.** *Drug and Alcohol Dependence*, 221, 108636.

175. Taylor, N, Miller, P, Coomber, K, Livingston, M, **Scott, D**, Buykx, P & Chikritzhs, T. (2021). **The impact of a minimum unit price on wholesale alcohol supply trends in the Northern Territory, Australia.** *Australian and New Zealand Journal of Public Health*, 45(1), 26-33.

176. Tenzin, T, Karki, R, Duba, T, Jamphele, K, Dhendup, S, Subba, DK, Dorji, G, Miller, PG, Connor, J, Barker, D, **O'Brien, KS** & Kypri, K. (2021). **Prevalence of drink-driving in Thimphu, Bhutan: Targeted surveillance at sentinel sites.** *Drug and Alcohol Review*, 40(3), 454-458.

177. Tiego, J, Chamberlain, SR, Harrison, BJ, Dawson, A, **Albertella, L**, Youssef, GJ, Fontenelle, LF & **Yücel, M.** (2020). **Heritability of overlapping impulsivity and compulsivity dimensional phenotypes.** *Scientific Reports*, 10(1), 14378.

178. **Tran, T**, Castello, J, Taylor, SE, Hardidge, A, Cannizzaro, S, **George, J** & Elliott, RA. (2020). **Opioid Use and Appropriateness of Supply After Total Knee or Hip Arthroplasty: An Australian Perspective.** *Journal of the American Academy of Orthopaedic Surgeons*, 28(23), e980-e989.

179. **Tran, T**, Taylor, SE, **George, J**, Pisasale, D, Batrouney, A, Ngo, J, Stanley, B & Elliott, RA. (2020). **Evaluation of communication to general practitioners when opioid-naïve post-surgical patients are discharged from hospital on opioids.** *ANZ Journal of Surgery*, 90(6), 1019-1024.

180. Van Den Boom, W, del Mar Quiroga, M, Fetene, DM, Agius, PA, Higgs, PG, Maher, L, Hickman, M, StooVé, MA & **Dietze, PM.** (2021). **The Melbourne Safe Injecting Room Attracted People Most in Need of Its Service.** *American Journal of Preventive Medicine*, 61 (2), 217-224.

181. **Vandenberg, B**, Livingston, M & **O'Brien, K.** (2021). **When the pubs closed: beer consumption before and after the first and second waves of COVID-19 in Australia.** *Addiction*, 116(7), 1709-1715.

182. **Verdejo-Garcia, A** & Albein-Urios, N. (2021). **Impulsivity traits and neurocognitive mechanisms conferring vulnerability to substance use disorders.** *Neuropharmacology*, 183, 108402.

183. Vashishtha, R, Pennay, A, **Dietze, P** & Livingston, M. (2021). **Exploring the impact of secondary supply laws on adolescent drinking trends in Australia.** *Journal of Studies on Alcohol and Drugs*, 82 (1), 76-83.

184. Vashishtha, R, Pennay, A, **Dietze, P** & Livingston, M. (2021). **Trends in adolescent alcohol and other risky health- and school-related behaviours and outcomes in Australia.** *Drug and Alcohol Review*, 40 (6), 1071-1082.

185. Vashishtha, R, Pennay, A, **Dietze, P**, Marzan, MB, Room, R & Livingston, M. (2021). **Trends in adolescent drinking across 39 high-income countries: exploring the timing and magnitude of decline.** *European Journal of Public Health*, 31 (2), 424-431.

186. Verdejo-Garcia, A & Albein-Urios, N. (2021). Impulsivity traits and neurocognitive mechanisms conferring vulnerability to substance use disorders. *Neuropharmacology*, 183, 108402.

187. **Verdejo-Garcia, A** & Crossin, R. (2021). **Nutritional and metabolic alterations arising from stimulant use: A targeted review of an emerging field.** *Neuroscience and Biobehavioral Reviews*, 120, 303-306.

188. **Verdejo-Garcia, A**, Tiego, J, **Kakoschke, N**, Moskovsky, N, **Voigt, K**, Anderson, A, Koutoulogenis, J, **Lubman, DI** & Bellgrove, M. (2021). **A unified online test battery for cognitive impulsivity reveals relationships with real-world impulsive behaviours.** *Nature Human Behaviour*, 5, 1562-1577.

189. Walton, CC & **Liknaitzky, P.** (2020). **Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy.** *Journal of Applied Sport Psychology*.

190. Ward, B, Kippen, R, **Reupert, A**, Maybery, D, Agius, PA, Quinn, B, Jenkinson, R, Hickman, M, Sutton, K, Goldsmith, R & **Dietze, PM.** (2020). **Parent and child co-resident status among an Australian community-based sample of methamphetamine smokers.** *Drug and Alcohol Review*, 40(7), 1275-1280.

191. Ward, B, Lane, R, Quinn, B & **Russell, G.** (2021). **Qualitative understandings of access to primary care services for consumers who use methamphetamine.** *Australian Journal of General Practice*, 50(7), 505-510.

192. Watterson, JR, **Gabbe, B**, Rosenfeld, JV, Ball, H, Romero, L & **Dietze, P.** (2021). **Workplace intervention programmes for decreasing alcohol use in military personnel: A systematic review.** *BMJ Military Health*, 167(3), 192-200.

193. Wertheimer, G, Mathieson, S, Maher, CG, Lin, CWC, McLachlan, AJ, **Buchbinder, R**, Pearson, SA & Underwood, M. (2021). **The Prevalence of Opioid Analgesic Use in People with Chronic Noncancer Pain: Systematic Review and Meta-Analysis of Observational Studies.** *Pain medicine (Malden, Mass.)*, 22(2), 506-517.

194. Whatnall, M, Skinner, J, **Verdejo-Garcia, A**, **Carter, A**, Brown, RM, Andrews, ZB, Dayas, CV, Hardman, CA, Loxton, N, Sumithran, P & Burrows, T. (2021). **Symptoms of addictive eating: What do different health professions think?.** *Behavioral Sciences*, 11(5), 60.

195. **Wilson, J, Lam, T, Scott, D**, Crossin, R, Matthews, S, **Smith, K, Lubman, DI** & **Nielsen, S.** (2020). **'Extreme personal stress' and 'a lot of pain': Exploring the physical, mental and social contexts of extramedical pharmaceutical opioid use in Australian paramedic case descriptions'.** *Drug and Alcohol Review*. 39(7), 870-878.

196. **Witt, K**, Pirkis, J, **Scott, D, Smith, K** & **Lubman, D.** (2021). **Trajectories in suicide attempt method lethality over a five-year period: Associations with suicide attempt repetition, all-cause, and suicide mortality.** *PLoS ONE*, 16(1 January), e0245780.

197. Wright, C, **Dietze, PM**, Kuntsche, E, Livingston, M, Agius, PA, Room, R, Raggatt, M, Hellard, M & Lim, MSC. (2020). **Effectiveness of an ecological momentary intervention for reducing risky alcohol consumption among young adults: Protocol for a three-arm randomized controlled trial.** *JMIR Research Protocols*, 9(3), e14190.

198. Yeung, J-T, Livingston, M, Callinan, S, Wright, C, Kuntsche, E, Room, R & **Dietze, P.** (2020). **Effects of Question Type and Order When Measuring Peak Consumption of Risky Drinking Events.** *Alcohol and alcoholism (Oxford, Oxfordshire)*, 55(6), 631-640.

FURTHER INFORMATION

Any enquiries or comments regarding this publication including requests regarding use or reproduction should be directed to the Monash Addiction Research Centre

Monash University
Peninsula Campus
Level 3, Building G
Moorooduc Hwy
Frankston, VIC 3199

Tel: +61 3 9904 4262
Email: marc.info@monash.edu